Lat adapter molecule for enhanced t-cell signaling and method of use

ABSTRACT

LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No.13/319,263, filed Apr. 30, 2010 which claims priority to U.S.Provisional Patent Application Ser. No. 61/176,231, filed on May 7, 2009each of which are incorporated herein in there entireties.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH

This work was supported by the National Cancer Institute of the NationalInstitutes of Health. The government has certain rights in theinvention.

BACKGROUND

Immunotherapy for the treatment of cancer includes multiple basicstrategies. Four particular immunotherapy approaches have garnered asignificant amount of scientific attention and clinical interest. Firstis the use of general agents including cytokines such as interleukin-2(IL-2) to stimulate the immune system of the patient. However, thismethod is limited by the toxicity of IL-2. Second is the use of vaccinesto promote a specific immune response to a target antigen present ontumors, and preferably not present on normal cells. Antigens includewhole cells, proteins, peptides or a wide variety of immunizing vectors.Such methods are under active investigation. Current studies havefocused on improving response by adding additional factors to enhancethe immune response. Third is the use of antibodies capable of bindingvarious cell or tumor-specific antigens and coupled to various toxins.These reagents can, in certain settings, deplete cancer cells. Otherantibody therapies are directed at targeting inhibitory molecule in Tcells, which might be inhibiting a T cell response to a cancer. Fourth,some have used T cells expressing an appropriate T-cell receptor thatbinds to the specific target antigen to promote an immune response,known as adoptive cell therapy (ACT). This approach involves theidentification ex vivo of autologous or allogeneic lymphocytes withanti-tumor activity which are then infused into cancer patients, oftenalong with appropriate growth factors to stimulate their survival andexpansion in vivo.

ACT has substantial theoretical and practical advantages over theapproaches discussed above. It is necessary to identify only a smallnumber of anti-tumor cells with the appropriate properties that can thenbe expanded to large numbers ex vivo for treatment. Alternatively, byidentifying T-cell receptors (TCRs) that bind to the tumor antigens,expression constructs can be inserted into T-cells from the patient tobe treated. In vitro tests can identify the exact populations andeffector functions required for cancer regression, which can then beselected for expansion. Similar strategies can be used for the treatmentof viral infection, particularly chronic viral infection, by identifyingTCRs that bind viral antigens (e.g., from Epstein Barr virus, herpesvirus, human immunodeficiency virus). Such therapies can be used inconjunction with more traditional therapies.

ACT has been highly successful in the treatment of melanoma. Patientswith metastatic melanoma have a median survival of about 8 months with atwo year survival rate of about 10-15% with the two approved treatmentsfrom the FDA, IL-2 and dacarbazine. Using transfer of autologoustumor-infiltrating lymphocytes (TIL) after lymphodepleting chemotherapyresulted in objective responses in 51% of 35 heavily pretreated patientswith metastatic melanoma. (Dudley M E, et al. Cancer regression andautoimmunity in patients following clonal repopulation with anti-tumorlymphocytes. Science 2002; 298:850-854; Dudley M E, et al. Adoptive celltransfer therapy following non-myeloablative but lymphodepletingchemotherapy for the treatment of patients with refractory metastaticmelanoma. J. Clin. Oncol 2005; 23:2346-2357). Further studies haveconfirmed the efficacy of the method of treatment of metastaticmelanoma, particularly with myeloablating and lymphodepleting methods(Dudley, M E et al., Adoptive cell therapy for patients with metastaticmelanoma: Evaluation of intensive myeloablative chemoradiationpreparative regimens, J. Clin. Oncol. 2008; 5233-5239).

Treatment of melanoma using ACT has been successful at least in part dueto the ability to identify autologous T-cells that react with MART-1(Melanoma Antigen Recognized by T cells), and the subsequent cloning ofT-cell receptors (TCR) that bind to MART-1. However, identification ofT-cells having a high avidity for the desired antigen has proven to be achallenge as many of the tumor antigens are expressed during developmentor in one or more tissues in the body. Therefore, the T-cells expressingthe appropriate TCR were likely deleted during clonal selection. Methodsfor cloning of TCRs for binding specific antigens have been established(see, e.g., Dossett. M L et a., Adoptive immunotherapy of disseminatedleukemia with TCR-transduced, CD8+ T cells expressing a known endogenousTCR. Mol. Ther. 2009; 17:742-749). Such methods can include the cloningof an appropriate TCR from a non-human species, followed by alaninescanning, and subsequent mutational analysis to identify a TCR withhigher affinity or efficacy that could be transduced into a T-cell foruse in ACT (Parkhurst, M. R. et al., Characterization of geneticallymodified T-cell receptors that recognize the CEA:691-699 peptide in thecontext of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res.2009; 15:169-180). However, even after administration of T-cellsexpressing TCRs with high avidity for their target antigen, such cellscan become inhibited or inactivated for reasons that are not presentlyunderstood.

SUMMARY OF THE INVENTION

The invention provides compositions and methods to increase persistenceof signaling in T-cells.

The invention provides isolated, non-naturally occurring linker foractivation of T cells (LAT) polypeptides including at least an effectivefragment of a full-length mammalian LAT 1 having at least one mutationat one amino acid capable of being ubiquitylated. For example, theinvention provides at least an effective fragment of a full-length humanLAT 1 polypeptide (SEQ ID NO: 1) having at least one amino acidsubstitution at amino acid 52 or amino acid 204, or both; or at least aneffective fragment of a full-length mouse LAT 1 polypeptide (SEQ ID NO:2) comprising at least one amino acid substitution at amino acid 53 oramino acid 121, or both. In certain embodiments of the invention, theamino acid substitution comprises a substitution of lysine witharginine. The invention further provides nucleic acid sequences encodingthe polypeptide sequences of the invention.

The invention further provides an isolated cell or population of cellsincluding an isolated, non-naturally occuring LAT polypeptide includingat least an effective fragment of a full-length mammalian LAT 1 havingat least one mutation at one amino acid capable of being ubiquitylated.In certain embodiments of the invention, the cell includes a T-cellreceptor expressed on the surface of the cell, and capable ofinteracting with a specific target antigen, including a known specifictarget antigen. Specific target antigens include, but are not limitedto, tumor antigens, viral antigens, and parasitic antigens. In certainembodiments, the T-cell receptor has a known amino acid sequence. Incertain embodiments, the T-cell receptor is natively expressed by thecell. In certain embodiments, the T-cell receptor is expressedheterologously in the cell. In certain embodiments, the cell is a T-cellor a peripheral blood lymphocyte. In certain embodiments, the cellfurther includes a reporter construct to detect signaling through theT-cell receptor. For example, the cell can include a reporter geneoperably linked to a promoter responsive to signaling through a T-cellreceptor such as a jun promoter, an NFAT promoter, or an NF-kappa Bpromoter.

The invention also provides a mammal including LAT polypeptides havingat least an effective fragment of a full-length mammalian LAT 1 havingat least one mutation at one amino acid capable of being ubiquitylated.In certain embodiments, the LAT polypeptide is present in an isolatedmammalian cell in the animal. In certain embodiments, the LATpolypeptide is provided to the mammalian cell by treating a cell fromthe mammal ex vivo with an expression construct to express the LATpolypeptide. In certain embodiments, the LAT polypeptide is provided ina cell from a syngeneic mammal by treating a cell from the syngeneicmammal ex vivo with an expression construct to express the LATpolypeptide. In certain embodiments, the mammal is a transgenic mammal.In certain embodiments the mammal is a mouse.

The invention provides methods of increasing signaling in response to anagonist in T-cell receptor including expressing a LAT polypeptideincluding at least an effective fragment of a full-length mammalian LAT1 having at least one mutation at one amino acid capable of beingubiquitylated in the cell; and contacting the cell with a T-cellreceptor agonist whereby T-cell receptor signaling is increased in thecell expressing a LAT polypeptide having at least one mutation at oneamino acid capable of being ubiquitylated relative to a cell notexpressing a LAT polypeptide having at least one mutation at one aminoacid capable of being ubiquitylated. In certain embodiments, the methodfurther includes detecting an increase in T-cell receptor signaling.Methods of detecting an increase in T-cell receptor signaling include,but are not limited to, detecting at least one of an increase in calciumflux, an increase in Ras signaling, an increase in activation of proteintyrosine kinase, an increase in T-cell proliferation, a decrease inT-cell apoptosis, expression of a reporter gene operably linked to apromoter sequence selected from the group consisting of jun, NFAT andNF-KB; CD25 and CD69 surface expression, and IL-2 production. In anembodiment, the enhanced signaling in response to an agonist in T-cellreceptor is used to increase the effectiveness of Adoptive Cell Therapy(ACT).

The invention provides methods of improving the effectiveness of ACT byincreasing signaling in T cells by the use of at least an effectivefragment of a full-length mammalian LAT 1 having at least one mutationat one amino acid capable of being ubiquitylated. In an embodiment, theeffectiveness of ACT is enhanced for the treatment of cancer. In anembodiment, the effectiveness of ACT is enhanced for the treatment of aviral infection. In an embodiment, the effectiveness of ACT is enhancedfor the treatment of parasitic infection.

The invention provides methods of identifying a T-cell receptor forspecific binding to a known target antigen by providing a cellexpressing a T-cell receptor and a LAT polypeptide having at least onemutation at one amino acid capable of being ubiquitylated; contactingthe cell with a specific target antigen in a context recognized by aT-cell receptor; and detecting signaling through the T-cell receptorwherein signaling through the T-cell receptor is indicative of theT-cell receptor binding the specific target antigen. Methods ofdetecting an increase in T-cell receptor signaling include, but are notlimited to, detecting at least one of an increase in calcium flux, anincrease in Ras signaling, an increase in activation of protein tyrosinekinase, an increase in T-cell proliferation, a decrease in T-cellapoptosis, expression of a reporter gene operably linked to a promotersequence selected from the group consisting of jun, NFAT and NF-KB; CD25and CD69 surface expression, and IL-2 production.

The invention provides methods for characterizing a subject suspected ofsuffering from or suffering from a defect in T-cell signaling, includingproviding a sample from a subject suspected of suffering from orsuffering from a defect in T-cell signaling; detecting a mutation in LATwherein the mutation alters ubiquitylation of LAT; wherebyidentification of a mutation in LAT that alters ubiquitylation of LATcharacterizes the subject having a defect in T-cell signaling. Incertain embodiments, the mutation comprises a mutation at one or moreamino acids of human LAT at amino acid 52 or amino acid 204. In certainembodiments, the mutation of an amino acid includes a point mutation ofthe amino acid or a deletion of the amino acid. In certain embodiments,the mutation in LAT is detected by a method comprising a functionalassay.

The invention provides isolated, non-naturally occurring double strandedRNA oligonucleotide duplex comprising from about 19 to about 24nucleotides connected by covalent linkages, wherein one strand of theoligonucleotide duplex comprises a nucleobase sequence specificallyhybridizable with nucleotides GCACAUCCUCAGAUAGUUU (SEQ ID NO: 5) whichtargets nucleotides 113-131 (from +1 at the ATG); CAAACGGCCUCACACGGUU(SEQ ID NO: 6) which targets nucleotides 153-171; GGACGACUAUCACAACCCA(SEQ ID NO: 7) which targets nucleotides 372-390; CCAACAGUGUGGCGAGCUA(SEQ ID NO: 8) which targets nucleotides 311-329 and CGUGUAGGAGUCUAUCAAA(SEQ ID NO: 9) which targets the antisense strand of nucleotides311-329. Such compositions include a first strand having a sequence ofGCACAUCCUCAGAUAGUUU (SEQ ID NO: 5); CAAACGGCCUCACACGGUU (SEQ ID NO: 6);GGACGACUAUCACAACCCA (SEQ ID NO: 7); CCAACAGUGUGGCGAGCUA (SEQ ID NO: 8);or CGUGUAGGAGUCUAUCAAA (SEQ ID NO: 9); and a second strand of RNAcomplementary thereto. In certain embodiments, the double stranded RNAoligonucleotide duplex is a siRNA or a shRNA. When the double strandedoligonucleotide is a siRNA, one or preferably both strands furtherinclude an AA nucleotide sequence on the 3′ end. In certain embodiments,the isolated, non-naturally occurring double stranded RNAoligonucleotide duplex is present in a cell.

The invention provides kits including any of the compositions of theinvention, or compositions for practicing any methods of the inventionin appropriate packaging and/or with instructions for use.

DEFINITIONS

An “agent” is understood herein to include a therapeutically activecompound or a potentially therapeutic active compound. An agent can be apreviously known or unknown compound. As used herein, an agent istypically a non-cell based compound, however, an agent can include abiological therapeutic agent, e.g., peptide or nucleic acid therapeutic,cytokine, antibody, etc.

An “agonist” is understood herein as a chemical substance capable ofinitiating the same reaction or activity typically produced by thebinding of an endogenous substance or ligand (e.g., antigen) to itsreceptor (e.g., TCR). An “antagonist” is understood herein as a chemicalsubstance capable of inhibiting the reaction or activity typicallyproduced by the binding of an endogenous substance (e.g., an endogenousagonist) to its receptor to prevent signaling through a receptor or toprevent downstream signaling that is the normal result of activation ofthe receptor. The antagonist can bind directly to the receptor or canact through other proteins or factors required for signaling. Agonistsand antagonists can modulate some or all of the activities of theendogenous substance or ligand that binds to the receptor. Antagonistsare typically characterized by determining the amount of the antagonistis required to inhibit the activity of the endogenous agonist. Forexample, an inhibitor at 0.01-, 0.1-, 1-, 5-, 10-, 50-, 100-, 200-,500-, or 1000-fold molar concentration relative to the agonist caninhibit the activity of the agonist by at least 10%, 50%, 90%, or more.T-cell receptor agonists include CD3.

As used herein “amelioration” or “treatment” is understood as meaning tolessen or decrease at least one sign, symptom, indication, or effect ofa specific disease or condition. For example, amelioration or treatmentof cancer can be determined using the standard RECIST (ResponseEvaluation Criteria in Solid Tumors) criteria including the assessmentof tumor burden, by survival time, reduced presence of tumor markers(e.g., prostate specific antigen), or any other clinically acceptableindicators of disease state or progression. Amelioration or treatment ofa viral or parasitic infection can be determined by viral or parasiteload, or secondary symptoms of the infection which vary with theparticular pathogen. Amelioration and treatment can require theadministration of more than one dose of an agent or therapeutic.Amelioration and treatment can include the prevention of a recurrence ofcancer at the same site or a remote site. As used herein, “prevention”is understood as to limit, reduce the rate or degree of onset, orinhibit the development of at least one sign or symptom of a disease orcondition. For example, a subject having a genetic predisposition todevelop a disease may develop disease later in life, e.g., delay ofBRCA1 or BRCA2 related breast cancer development from third or fourthdecade of life to fifth or beyond. Prevention can include reducing theincidence in a population of infection with a specific pathogen, ordelaying infection in an individual repeatedly exposed to the particularpathogen. Prevention can require the administration of more than onedose of an agent or therapeutic.

A “cell based therapeutic” as used herein is understood as a compositionincluding a live cell for prevention, amelioration, or treatment of adisease or disorder. The cell can be from the subject to be treated orfrom a heterologous subject. The cell can be manipulated ex vivo afterobtaining the cell from the source, and prior to administration of thecell to the subject for use as a therapeutic. Manipulations can include,but are not limited to, cell sorting, culturing, treatment withcytokines or growth factors, and transfection.

“Contacting a cell” is understood herein as providing an agent orisolated cell (e.g., T-cell expressing a selected TCR) to a test cell orcell to be treated in culture or in an animal, such that the agent orisolated cell can interact with the surface of the test cell or cell tobe treated, potentially be taken up by the test cell or cell to betreated, and have an effect on the test cell or cell to be treated. Theagent or isolated cell can be delivered to the cell directly (e.g., byaddition of the agent to culture medium or by injection into the cell ortissue of interest), or by delivery to the organism by an enteral orparenteral route of administration for delivery to the cell bycirculation, lymphatic, or other means.

As used herein, “changed as compared to a control” sample or subject isunderstood as having a level of the analyte or diagnostic or therapeuticindicator to be detected at a level that is statistically different thana sample from a normal, untreated, or control sample. Control samplesinclude, for example, cells in culture, one or more laboratory testanimals, or one or more human subjects. Methods to select and testcontrol samples are within the ability of those in the art. An analytecan be a naturally occurring substance that is characteristicallyexpressed or produced by the cell or organism (e.g., PSA) or a substanceproduced by a reporter construct (e.g, β-galactosidase or luciferase).Depending on the method used for detection the amount and measurement ofthe change can vary. For example, a change in the amount of cleavage ofanalyte present will depend on the exact reaction conditions and theamount of time after exposure to the agent the sample is collected.Changed as compared to a control reference sample can also includedecreased binding of a ligand to a receptor in the presence of anantagonist or other inhibitor. Determination of statistical significanceis within the ability of those skilled in the art.

As used herein “characterizing a subject suspected of comprising orcomprising a defect in T-cell signaling” is understood as the process ofobtaining a sample from a subject having or suspected of having a defector other alteration in T-cell signaling as demonstrated, for example, bythe detection of an autoimmune disorder or an immunodeficiency disorder,particularly when the disorder is of an unknown etiology, and analyzingthe sample for an alteration of the sequence of LAT protein,particularly at a ubiquitylation site, or the expression level of LATprotein.

As used herein, “detecting”, “detection” and the like are understoodthat an assay performed for identification of a specific analyte in asample or a product from a reporter construct in a sample. Detection canalso include identification of activation of a kinase or other enzyme,or a change in calcium channel gating by the detection of a calciumflux. Detection can include the identification of a mutation in a genesequence, such as a point mutation, a deletion of all or part of thecoding sequence or transcriptional/translational regulatory sequences ofthe gene, a truncation of the gene sequence, or any other alterationthat can alter the expression level or the sequence of the proteinexpressed by the gene, particularly when the alteration of the sequenceresults in a phenotypic change in the subject. The amount of analytedetected in the sample can be none or below the level of detection ofthe assay or method.

As used herein, a “diagnostic marker” is understood as one or more signsor symptoms of a disease or condition that can be assessed, preferablyquantitatively to monitor the progress or efficacy of a diseasetreatment or prophylactic treatment or method. A diagnostic marker canbe a substance that is released by a tumor (e.g., antigens such as PSAor enzymes). A diagnostic marker can be tumor size. A diagnostic markercan be a change in blood counts or cellular function measured in an invitro assay, or the presence and characteristics of metastases (numberand size).

As used herein, the terms “effective” and “effectiveness” includes bothpharmacological effectiveness and physiological safety. Pharmacologicaleffectiveness refers to the ability of the treatment to result in adesired biological effect in the patient. Physiological safety refers tothe level of toxicity, or other adverse physiological effects at thecellular, organ and/or organism level (often referred to asside-effects) resulting from administration of the treatment. On theother hand, the term “ineffective” indicates that a treatment does notprovide sufficient pharmacological effect to be therapeutically useful,even in the absence of deleterious effects, at least in the unstratifiedpopulation. (Such a treatment may be ineffective in a subgroup that canbe identified by the expression profile or profiles.) “Less effective”means that the treatment results in a therapeutically significant lowerlevel of pharmacological effectiveness and/or a therapeutically greaterlevel of adverse physiological effects, e.g., greater liver toxicity.

Thus, in connection with the administration of a drug, a drug which is“effective against” a disease or condition indicates that administrationin a clinically appropriate manner results in a beneficial effect for atleast a statistically significant fraction of patients, such as aimprovement of symptoms, a cure, a reduction in disease signs orsymptoms, extension of life, improvement in quality of life, or othereffect generally recognized as positive by medical doctors familiar withtreating the particular type of disease or condition.

“Expression construct” as used herein is understood as a nucleic acidsequence including a sequence for expression as a polypeptide or nucleicacid (e.g., siRNA, shRNA) operably linked to a promoter and otheressential regulatory sequences to allow for the expression of thepolypeptide in at least one cell type. In a preferred embodiment, thepromoter and other regulatory sequences are selected based on the celltype in which the expression construct is to be used. Selection ofpromoter and other regulatory sequences for protein expression are wellknown to those of skill in the art. An expression constructionpreferably also includes sequences to allow for the replication of theexpression construct, e.g., plasmid sequences, viral sequences, etc. Forexample, expression constructs can be incorporated into replicationcompetent or replication deficient viral vectors including, but notlimited to, adenoviral (Ad) vectors, adeno-associated viral (AAV)vectors of all serotypes, self-complementary AAV vectors, andself-complementary AAV vectors with hybrid serotypes, self-complementaryAAV vectors with hybrid serotypes and altered amino acid sequences inthe capsid that provide enhanced transduction efficiency, lentiviralvectors, retroviral vectors, or plasmids for bacterial expression.

As used herein, “heterologous” as in “heterologous protein” isunderstood as a protein not natively expressed in the cell in which itis expressed. The heterologous protein may be, but need not be, from adifferent species. For example, during development, recombination andselection occurs in T-cells such that each T-cell expresses a singlenative TCR. A heterologous TCR can be expressed in a T-cell thatexpresses a different native TCR, a peripheral blood lymphocyte thatdoes not express a TCR, or a cell in culture (e.g., a Jurkat cell) thatdoes not express the specific TCR being expressed.

As used herein, “isolated” or “purified” when used in reference to apolypeptide means that a naturally occurring polypeptide or protein hasbeen removed from its normal physiological environment (e.g., proteinisolated from plasma or tissue) or is synthesized in a non-naturalenvironment (e.g., artificially synthesized chemically or in aheterologous system). Thus, an “isolated” or “purified” polypeptide canbe in a cell-free solution or placed in a different cellular environment(e.g., expressed in a heterologous cell type). The term “purified” doesnot imply that the polypeptide is the only polypeptide present, but thatit is essentially free (about 90-95%, up to 99-100% pure) of cellular ororganismal material naturally associated with it, and thus isdistinguished from naturally occurring polypeptide. Similarly, anisolated nucleic acid is removed from its normal physiologicalenvironment. “Isolated” when used in reference to a cell means the cellis in culture (i.e., not in an animal), either cell culture or organculture, of a primary cell or cell line. Cells can be isolated from anormal animal, a transgenic animal, an animal having spontaneouslyoccurring genetic changes, and/or an animal having a genetic and/orinduced disease or condition. Isolated cells can be further modified toinclude nucleic acids for the expression of heterologous T-cellreceptors and/or wild-type or modified LAT proteins; reporterconstructs; or be treated with various stimuli to modulate expression ofa gene of interest.

As used herein, “kits” are understood to contain at least thenon-standard laboratory reagents for use in the methods of theinvention, such as cDNAs or nucleic acid constructs encoding wild-typeor modified LAT proteins for the use in the methods of the invention.The invention can further include TCRs and the corresponding antigen orantigens, or non-specific T-cell agonists such as CD3. One or more cellsor cell lines expressing LAT proteins with or without reporterconstructs can be included in the kit. Constructs or cDNAs to expressone or more TCRs can also be included. The kit can further include anyother components required to practice the method of the invention, asdry powders, concentrated solutions, or ready to use solutions. In someembodiments, the kit comprises one or more containers that containreagents for use in the methods of the invention; such containers can beboxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, orother suitable container forms known in the art. Such containers can bemade of plastic, glass, laminated paper, metal foil, or other materialssuitable for holding reagents.

As used herein, a “LAT polypeptide” is understood a sequence ofcontiguous amino acids of a sequence provided by at least one of GenBankNo. NP_(—)001014987 (Homo sapien, SEQ ID NO: 1), XP_(—)001147360.1 (Pantroglodytes), XP_(—)001102058.1 (Macaca mulatto), XP_(—)001502393.1(Equus caballus), NP_(—)110480 (Rattus norvegicus), NP_(—)034819 (Musmusculus, SEQ ID NO: 2), XP_(—)849910.1 (Canis familiaris), andNP_(—)001098448 (Bos taurus), in the version available on the day offiling of the instant application, having a length of at least 50 aminoacids, at least 60 amino acids, at least 70 amino acids, at least 80amino acids, at least 90 amino acids, at least 100 amino acids, at least125 amino acids, at least 150 amino acids, at least 175 amino acids, atleast 200 amino acids, at least 210 amino acids, or at least 220 aminoacids. In an embodiment, a LAT polypeptide further includes one or moreamino acid deletions or substitutions such that the LAT polypeptide isat least 80% identical, 85% identical, 90% identical, 95% identical, 97%identical, 98% identical, 99% identical to at least 50 amino acids, atleast 60 amino acids, at least 70 amino acids, at least 80 amino acids,at least 90 amino acids, at least 100 amino acids, at least 125 aminoacids, at least 150 amino acids, at least 175 amino acids, at least 200amino acids, at least 210 amino acids, or at least 220 amino acids of anamino acid sequence provided by one of the GenBank numbers set forthabove. Mutations can be conservative mutations, or non-conservativemutations. Conservative mutations replace an amino acid with an aminoacid having similar structural and/or chemical properties. Amino acidsare typically grouped based on the properties of their side chains Forexample, Lysine, arginine, and histidine are basic amino acids. Asparticacid and glutamic acid have acidic side chains Glycine, alanine, valine,leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, andcysteine have non-polar side chains Asparagine, glutamine, serine,threonine, and tyrosine have uncharged side chains.

A LAT polypeptide can be encoded a native nucleic acid sequence such asthose provided by GenBank numbers NM_(—)001014987 (Homo sapien, SEQ IDNO: 3), XM_(—)001147360 (Pan troglodytes), XM_(—)001502343.1 (Equuscaballus), NM_(—)030853.1 (Rattus norvegicus), NM_(—)010689 (Musmusculus, SEQ ID NO: 4), XM_(—)844817.1 (Canis familiaris), andNM_(—)001104978.1 (Bos taurus). Alternatively, a LAT polypeptide can beencoded by any nucleotide sequence that provides a polypeptide havingthe sequence of a LAT polypeptide. The degeneracy of the genetic code iswell understood such that the native nucleic acid sequence can besubstantially modified without altering the sequence of the amino acidencoded. LAT polypeptide sequences and LAT nucleic acid sequences areprovided, for example in U.S. Pat. No. 7,118,889 which is incorporatedherein by reference. An active fragment of a LAT polypeptide includes atruncated, mutated, or full length version of the LAT protein from anyspecies wherein the active fragment of LAT can support signaling througha T-cell receptor as determined using any of the methods provided in theExamples below, for example by a calcium flux assay, a kinase assay, ora reporter construct assay in a T cell that does not express andendogenous LAT (e.g., JCam 2.5 cells) at a statistically significantlevel over background in a cell not expressing any active fragment ofLAT. In an embodiment, an active fragment of LAT can support signalingthrough a T cell receptor at a level of at least 10% of that supportedby a wild-type LAT polypeptide using any of the methods provided in theExamples below.

The term “label” or “detectable label” as used herein refers to any atomor molecule which can be used to provide a detectable (preferablyquantifiable) signal, and which can be attached to a nucleic acid orprotein. Labels may provide signals detectable by fluorescence,radioactivity, colorimetry, gravimetry, X-ray diffraction or absorption,magnetism, enzymatic activity, and the like. Various methods of labelingpolypeptides and glycoproteins are known in the art and may be used.Examples of labels for polypeptides include, but are not limited to, thefollowing: radioisotopes (e.g., ³H), fluorescent labels (e.g., FITC,rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradishperoxidase, beta-galactosidase, luciferase, alkaline phosphatase),biotinyl groups, predetermined polypeptide epitopes recognized by asecondary reporter (e.g., leucine zipper pair sequences, binding sitesfor secondary antibodies, metal binding domains, epitope tags). In someembodiments, labels are attached by spacer arms of various lengths toreduce potential steric hindrance. In others, the label is part of thefusion protein, e.g. Green Fluorescent Protein (GFP), Yellow FluorescentProtein (YFP).

A “non-naturally occurring” polypeptide sequence or nucleic acidsequence and the like is an amino acid or nucleotide sequence that isnot present in the proteome or the genome, respectively, of the organismfrom which the sequence is derived. In certain embodiments, the aminoacid or nucleotide sequence can include one or more mutations that havenot been identified as naturally occurring mutations. In certainembodiments, the amino acid or nucleotide sequence can be a truncatedsequence or a sequence with one or more internal deletions. In certainembodiments, the amino acid or nucleotide sequence can be fused toanother amino acid or nucleotide sequence, e.g., a coding sequence, aregulatory sequence, etc., that confers a new property to the sequencenot present in the naturally occurring sequence. A non-naturallyoccurring polypeptide sequence or nucleic acid sequence can include oneor more non-naturally occurring amino acids or nucleic acids.

“Obtaining” is understood herein as manufacturing, purchasing, orotherwise coming into possession of.

As used herein, “oligonucleotide sequence” is understood as a non-codingnucleic acid sequence prepared by chemical synthesis methods or bytranscription from a construct including an appropriate promotersequence. A double stranded RNA oligonucleotide sequence as used hereinincludes a single strand forming a hairpin structure (e.g., shRNA) orjoined by other non-nucleic acid linkages, or two separate strandsannealed to form a double stranded structure.

A “parasitic antigen” as used herein is any protein or nucleic acid, orfragment thereof; from a parasite that can infect a subject, in thecontext of the invention, preferably an mammalian subject, andpreferably on the surface of the cell to allow the antigen to berecognized by a TCR.

The phrase “pharmaceutically acceptable carrier” is art recognized andincludes a pharmaceutically acceptable material, composition or vehicle,suitable for administering compounds of the present invention tomammals. The carriers include liquid or solid filler, diluent,excipient, solvent or encapsulating material, involved in carrying ortransporting the subject agent from one organ, or portion of the body,to another organ, or portion of the body. Each carrier must be“acceptable” in the sense of being compatible with the other ingredientsof the formulation and not injurious to the patient. For example,pharmaceutically acceptable carriers for administration of cellstypically is a carrier acceptable for delivery by injection, and do notinclude agents such as detergents or other compounds that could damagethe cells to be delivered. Some examples of materials which can serve aspharmaceutically acceptable carriers include: sugars, such as lactose,glucose and sucrose; starches, such as corn starch and potato starch;cellulose, and its derivatives, such as sodium carboxymethyl cellulose,ethyl cellulose and cellulose acetate; powdered tragacanth; malt;gelatin; talc; excipients, such as cocoa butter and suppository waxes;oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil,olive oil, corn oil and soybean oil; glycols, such as propylene glycol;polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol;esters, such as ethyl oleate and ethyl laurate; agar; buffering agents,such as magnesium hydroxide and aluminum hydroxide; alginic acid;pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol;phosphate buffer solutions; and other non-toxic compatible substancesemployed in pharmaceutical formulations.

Wetting agents, emulsifiers and lubricants, such as sodium laurylsulfate and magnesium stearate, as well as coloring agents, releaseagents, coating agents, sweetening, flavoring and perfuming agents,preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically acceptable antioxidants include: watersoluble antioxidants, such as ascorbic acid, cysteine hydrochloride,sodium bisulfate, sodium metabisulfite, sodium sulfite and the like;oil-soluble antioxidants, such as ascorbyl palmitate, butylatedhydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propylgallate, a-tocopherol, and the like; and metal chelating agents, such ascitric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaricacid, phosphoric acid, and the like.

Formulations of the present invention include those suitable for oral,nasal, topical, transdermal, buccal, sublingual, intramuscular,intravenous, intraarterial, intraperotineal, rectal, vaginal and/orvarious parenteral administration routes. The formulations mayconveniently be presented in unit dosage form and may be prepared by anymethods well known in the art of pharmacy. The amount of activeingredient that can be combined with a carrier material to produce asingle dosage form will generally be that amount of the compound thatproduces a therapeutic effect.

As used herein, “plurality” is understood to mean more than one. Forexample, a plurality refers to at least two, three, four, five, or more.

A “polypeptide” or “peptide” as used herein is understood as two or moreindependently selected natural or non-natural amino acids joined by acovalent bond (e.g., a peptide bond). A peptide can include 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more naturalor non-natural amino acids joined by peptide bonds. Polypeptides asdescribed herein include full length proteins (e.g., fully processedproteins) as well as shorter amino acids sequences (e.g., fragments ofnaturally occurring proteins or synthetic polypeptide fragments).

“Reporter construct” as used herein is understood to be an exogenouslyinserted gene, often present on a plasmid, with a detectable geneproduct, under the control of a promoter sequence. The activity of thepromoter is modulated upon signaling through the TCR pathway. A plasmidcontaining the c-jun promoter upstream of a reporter can be transfectedinto T-cell cell line, e.g., Jurkat cells, CCRF-CEM cells, CML-T1 cells.Preferably, the gene product is easily detectable using a quantitativemethod. Common reporter genes include luciferase and beta-galactosidase.The reporter construct can be transiently inserted into the cell bytransfection or infection methods. Alternatively, stable cell lines canbe made using methods well known to those skilled in the art, or cellscan be obtained from transgenic animals expressing a reporter construct.The specific reporter gene or method of detection is not a limitation ofthe invention.

“RNA interference” refers to a target directed disruption of expressionfrom a particular RNA transcript using a double stranded RNA molecule,either a siRNA or a shRNA. “siRNA” refers to a small interfering RNA,sometimes known as short interfering RNA or silencing RNA, is a class of20-25 nucleotide-long double-stranded RNA molecules involved in the RNAinterference (RNAi) pathway, where it interferes with the expression ofa specific gene. SiRNAs have a well-defined structure: a short (usually21-nt) double strand of RNA (dsRNA) with 2-nt 3′ overhangs on eitherend. However, siRNAs can vary in length from about 19 to about 24nucleotides in length. Each strand has a 5′ phosphate group and a 3′hydroxyl (—OH) group. Structures of siRNAs and methods for design areprovided, for example in WO02/44321, incorporated herein by reference.As used herein, “small hairpin RNA” or “short hairpin RNA” (shRNA) is asequence of RNA that makes a tight hairpin turn that can be used tosilence gene. A shRNA is composed of a single-stranded RNA with twoself-complementary regions that allow the RNA to fold back upon itselfand form a stem-loop structure with an intramolecular duplex region andan unpaired loop region.

A “sample” as used herein refers to a biological material that isisolated from its environment (e.g., blood or tissue from an animal,cells, or conditioned media from tissue culture) and is suspected ofcontaining, or known to contain an analyte, such as a tumor cell or aproduct from a reporter construct. A sample can also be a partiallypurified fraction of a tissue or bodily fluid. A reference sample can bea “normal” sample, from a donor not having the disease or condition, orfrom a normal tissue in a subject having the disease or condition (e.g.,normal tissue vs. tumor tissue). A reference sample can also be from anuntreated donor or cell culture not treated with an active agent (e.g.,no treatment or administration of vehicle only) and/or stimulus. Areference sample can also be taken at a “zero time point” prior tocontacting the cell or subject with the agent or cell to be tested.

“Small molecule” as used herein is understood as a compound, typicallyan organic compound, having a molecular weight of no more than about1500 Da, 1000 Da, 750 Da, or 500 Da. In an embodiment, a small moleculedoes not include a polypeptide or nucleic acid.

A TCR “specifically binds” a target antigen when the target antigen isbound with at least 100-fold, preferably at least 500-fold, preferablyat least 1000-fold preference as compared to a non-specific antigen or apool of non-specific antigens, and wherein specific binding of thetarget antigen to the TCR promotes signaling through the TCR. Preferencefor binding of a specific antigen can be determined, for example, by useof cellular assays such as for proliferation, cytokine production orcytolytic activity on specific targets. More rigorously one can performbinding assays of particular TCRs on appropriate peptide-MHC complexes.The antigen can be a self-antigen or a non-self antigen.

A “subject” as used herein refers to living organisms. In certainembodiments, the living organism is an animal. In certain preferredembodiments, the subject is a mammal. In certain embodiments, thesubject is a domesticated mammal. Examples of subjects include humans,non-human primates, monkeys, dogs, cats, mice, rats, cows, horses,goats, and sheep. A human subject may also be referred to as a patient.

A subject “suffering from or suspected of suffering from” a specificdisease, condition, or syndrome has a sufficient number of risk factorsor presents with a sufficient number or combination of signs or symptomsof the disease, condition, or syndrome such that a competent individualwould diagnose or suspect that the subject was suffering from thedisease, condition, or syndrome. Methods for identification of subjectssuffering from or suspected of suffering from conditions such as cancer,or viral or parasitic infection is within the ability of those in theart. Subjects suffering from, and suspected of suffering from, aspecific disease, condition, or syndrome are not necessarily twodistinct groups.

As used herein, “T-cell receptor” or “TCR” is a molecule found on thesurface of T lymphocytes (or T cells). TCRs recognize antigens in thecontext of a major histocompatibility complex (MHC) molecule present onthe surface of an antigen presenting cell, or in the context of cellsurface expression (e.g., expressed on a tumor cell or a virallyinfected cell). A T-cell receptor is a heterodimer consisting ofantigen-MHC binding, clonotypic alpha and beta chains in about 95% of Tcells, and consisting of gamma and delta chains in about 5% of T-cells.The CD3-and ζ-chains, together with the alpha and beta TCR chains, formwhat is known as the T cell receptor. Engagement of the TCR with antigenand MHC results in activation of its T lymphocyte through a series ofbiochemical events mediated by associated enzymes, co-receptors, andaccessory molecules, including LAT.

As used herein, “T-cell receptor signaling” as used herein is understoodas a series of inter-related events initiated by the binding of either anon-specific (e.g., anti-CD3 antibody) or a specific (antigen presentedby an MHC) ligand to a TCR and resulting in a number of responses by thecell in which the TCR is expressed. When the TCR expressed in a T-cellis activated the responses include kinase activation includingactivation of Lck and/or Fyn and ZAP-70 protein tyrosine kinases,activation of the serine protein kinase, protein kinase C, intracellularcalcium flux, translocation of transcription factors to the nucleusincluding c-jun and NFAT, cytoskeletal remodeling due to activation ofRac and CDC42, cell proliferation, phosphoinositide (PI) turnover,decreased apoptosis, CD69 expression, secretion of cytokines such asIL-2 and in the case of cytolytic T cells, lysis of appropriate targetcells.

“Target antigen” is understood as any peptide, nucleic acid, hapten, orother small molecule to which a TCR can specifically bind. The peptideor nucleic acid can be a protein fragment or a nucleic acid fragmentfrom the subject or a pathogenic agent (e.g., virus, parasite). Thefragment can be a naturally occurring fragment, e.g., a fragment of aprocessed protein presented in an MHC by an antigen presenting cell, ora peptide selected for potential antigenic properties, targetspecificity, or other desired properties.

“Therapeutically effective amount,” as used herein refers to an amountof an agent which is effective, upon single or multiple doseadministration to the cell or subject, in prolonging the survivabilityof the patient with such a disorder beyond that expected in the absenceof such treatment.

An agent can be administered to a subject, either alone or incombination with one or more therapeutic agents, as a pharmaceuticalcomposition in mixture with conventional excipient, e.g.,pharmaceutically acceptable carrier, or therapeutic treatments such asradiation.

The pharmaceutical agents may be conveniently administered in unitdosage form and may be prepared by any of the methods well known in thepharmaceutical arts, e.g., as described in Remington's PharmaceuticalSciences (Mack Pub. Co., Easton, Pa., 1980). Formulations for parenteraladministration may contain as common excipients such as sterile water orsaline, polyalkylene glycols such as polyethylene glycol, oils ofvegetable origin, hydrogenated naphthalenes and the like. In particular,biocompatible, biodegradable lactide polymer, lactide/glycolidecopolymer, or polyoxyethylene-polyoxypropylene copolymers may be usefulexcipients to control the release of certain agents.

It will be appreciated that the actual preferred amounts of activecompounds used in a given therapy will vary according to e.g., thespecific compound being utilized, the particular composition formulated,the mode of administration and characteristics of the subject, e.g., thespecies, sex, weight, general health and age of the subject. Optimaladministration rates for a given protocol of administration can bereadily ascertained by those skilled in the art using conventionaldosage determination tests conducted with regard to the foregoingguidelines.

The nucleic acids for expression of the peptides of the invention can,for example, be administered ex vivo, with a dosage ranging from about0.001 μg to about 1000 μg, depending upon various factors including thenumber of cells to which the constructs should be delivered. effectivedosages would range from about 1 μg to about 100 μg, that is about 10 μgto about 50 μg, about 0.1 μg to about 10 μg, about 1 μg to about 20 μg,or any range bracketed by any of the two values listed, for an adultliver. Dosages can be adjusted for the size of the plasmid or viralvector to be delivered. It is understood that if the nucleic acid is tobe delivered systemically, higher doses will be used.

For administration of viral particles ex vivo, dosages are typicallyprovided by number of virus particles (or viral genomes) and effectivedosages would range from about 1×10¹⁰ to 1×10¹⁴ particles, about 1×10¹⁰to 1×10¹³ particles, about 1×10¹¹ to 1×10¹⁴ particles, about 1×10¹² to1×10¹⁴ particles, or about 1×10⁹ to 1×10¹⁵ particles delivered to the Tcells. The effective dose can be the number of particles delivered foreach expression construct to be delivered when different expressionconstructs encoding different genes are administered separately. Inalternative embodiment, the effective dose can be the total number ofparticles administered, of one or more types. The methods hereincontemplate administration of an effective amount of compound orcompound composition to achieve the desired or stated effect. It isunderstood that if the nucleic acid is to be delivered systemically,higher doses will be used.

The term “transfection” as used herein refers to the introduction of atransgene into a cell. The term “transgene” as used herein refers to anynucleic acid sequence which is introduced into the genome of a cell byexperimental manipulations. Transfection may be accomplished by avariety of means known to the art including calcium phosphate-DNAco-precipitation, DEAE-dextran-mediated transfection, polybrene-mediatedtransfection, electroporation, microinjection, liposome fusion,lipofection, protoplast fusion, retroviral infection, biolistics (i.e.,particle bombardment) and the like.

The term “stable transfection” or “stably transfected” refers to theintroduction and integration of a transgene into the genome of thetransfected cell. The term “stable transfectant” refers to a cell whichhas stably integrated one or more transgenes into the genomic DNA.

The term “transient transfection” or “transiently transfected” refers tothe introduction of one or more transgenes into a transfected cell inthe absence of integration of the transgene into the host cell's genome.The term “transient transfectant” refers to a cell which has transientlyintegrated one or more transgenes.

“Tumor antigen” as used herein can be any antigen expressed exclusivelyor preferentially in tumor cells, including, but not limited to, MART-1,gp100, carcinoembryonic antigen (CEA; CEACAM5; CD66e), cancer-testisantigen (NY-ESO-1), alphafetoprotein (AFP), CA-125 (cancer antigen-125,MUC-16), mucin 1 (MUC-1), epithelial tumor antigen (ETA), tyrosinase,and melanoma-associated antigen (MAGE).

A “viral antigen” as used herein is any protein or nucleic acid, orfragment thereof from a virus that can infect a cell, in the context ofthe invention, preferably a mammalian cell, and preferably on thesurface of the cell bound to the MHC molecule to allow the antigen to berecognized by a TCR. As used herein, viral antigens are preferably fromviruses that produce chronic or sustained infections including, but notlimited to, herpes viruses, human immunodeficiency viruses, andhepatitis viruses.

The term “wild-type” or “WT” refers to a gene or gene product which hasthe characteristics of that gene or gene product when isolated from anaturally occurring source. A wild-type gene is that which is mostfrequently observed in a population and is thus arbitrarily designatedthe “normal” or “wild-type” form of the gene. In contrast, the term“modified” or “mutant” refers to a gene or gene product which displaysmodifications (e.g. deletions, substitutions, etc.) in sequence and orfunctional properties (i.e., altered characteristics) when compared tothe wild-type gene or gene product. It is noted that naturally-occurringmutants can be isolated; these are identified by the fact that they havealtered characteristics when compared to the wild-type gene or geneproduct.

Ranges provided herein are understood to be shorthand for all of thevalues within the range. For example, a range of 1 to 50 is understoodto include any number, combination of numbers, or sub-range from thegroup consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

Unless specifically stated or obvious from context, as used herein, theterm “or” is understood to be inclusive.

Unless specifically stated or obvious from context, as used herein, theterms “a”, “an”, and “the” are understood to be singular or plural.

Unless specifically stated or obvious from context, as used herein, theterm “about” is understood as within a range of normal tolerance in theart, for example within 2 standard deviations of the mean. About can beunderstood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%,0.1%, 0.05%, or 0.01% of the stated value.

The recitation of a listing of chemical groups in any definition of avariable herein includes definitions of that variable as any singlegroup or combination of listed groups. The recitation of an embodimentfor a variable or aspect herein includes that embodiment as any singleembodiment or in combination with any other embodiments or portionsthereof.

All oligonucleotide sequences are written from the 5′-end to the 3′-endunless otherwise specifically noted.

Nucleic acids encoding the various polypeptide sequences can readily bedetermined by one of skill in the art, and any sequence encoding any ofthe polypeptide sequences of the invention falls within the scope of theinvention, as well as the complement of the coding sequence, and doublestranded nucleic acid sequences including coding sequences and theircomplement as well as artificial and non-naturally occurring sequencesand their complement.

Any compositions or methods provided herein can be combined with one ormore of any of the other compositions and methods provided herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A—Simplified schematic of proximal signaling in a T-cell.

FIG. 2A—Schematic of human LAT protein. FIG. 2B—Western blot ofimmunoprecipitates from cells transfected with expression vectorsencoding an HA-tagged ubiquitin and a wild-type or mutated version ofLAT as indicated.

FIG. 3—Graph of the time that LAT containing clusters persisted in cellsafter TCR stimulation in cells expressing wild-type LAT, mutant 2KR LAT,or cells co-expressing 70ZCbl with wild-type or mutant 2KR LAT.

FIG. 4A—Mean YFP levels of cells expressing wild-type LAT-YFP or 2KRLAT-YFP 24 hours after transfection pre-sort, post-sort and post-sort 24hrs in culture. FIG. 4B—Quantitative, real-time PCR results ofendogenous LAT, transfected LAT and beta-actin.

FIG. 5A—An autoradiograph of LAT protein lifetime in Jurkat JCam2.5cells expressing a wild-type or mutated version (2KRLAT) of LAT isresistant to ubiquitylation. FIG. 5B—Pulse chase analysis of cellstreated with proteasomal inhibitor MG-132, the lysosomal inhibitorleupeptin or a combination of the two. FIG. 5C—Quanatification of theautoradiographs shown in FIG. 5A. FIG. 5D—Quantification of theautoradiographs shown in FIG. 5B. FIG. 5E—Mean YFP levels in cellsexpressing wild-type or 2KR LAT-YFP incubated with proteasomal inhibitorMG-132.

FIG. 6A—Western blot analysis of whole cell lysates of LAT-deficientJurkat JCam2.5 cells stably expressing wild-type or 2KR LAT. FIG.6B—Cells were stimulated with CD3 antibody and calcium influx wasmonitored using a fluorescent dye INDO-1. FIG. 6C—Cells were stimulatedwith 10 μg/ml CD3 and CD69 levels were evaluated 16 hourspost-stimulation.

FIG. 7A—Jurkat E6.1 cells were transiently transfected with LATtargeting siRNA or control siRNA and control YFP plasmid, wild-typeLAT-YFP or 2KR LAT-YFP plasmids as indicated. Whole cell lysates wereprepared from the above-described transfected cells 48 hours aftertransfection. The levels of endogenous LAT, transfected LAT-YFP (upperpanel) and β-actin (lower panel) were assessed by immunoblotting. FIG.7B—Histogram showing wild-type LAT-YFP and 2KR LAT-YFP expression. Forfunctional assays described in C and D, cells falling within Gate Bexpressing equivalent levels of LAT-YFP protein were analyzed. FIG.7C—Transfected cells were stimulated with CD3 and cytosolic Ca⁺⁺ influxwas measured. FIG. 7D—CD69 upregulation was measured in transfectedcells 18 hrs after CD3 activation. FIG. 7E—NFAT luciferase activity wasmeasured in cells stimulated with various doses of CD3.

FIG. 8A—Primary human CD4+ cells were transiently transfected with LATtargeting siRNA or control siRNA and control YFP plasmid, wild-typeLAT-YFP or 2KR LAT-YFP plasmids as indicated. Whole cell lysates wereprepared from the above-described transfected cells 48 hours aftertransfection. The levels of endogenous LAT, transfected LAT-YFP (upperpanel) and β-actin (lower panel) were assessed by immunoblotting. FIG.8B—CD69 upregulation was measured in transfected cells 18hrs after CD3activation. FIG. 8C—Histogram showing wild-type LAT-YFP and 2KR LAT-YFPexpression.

FIG. 9A shows calcium fluxes in response to CD3 stimulation in cellstransfected with siRNA targeted to LAT. FIG. 9B and FIG. 9C show calciumfluxes in response to CD3 stimulation in cells transfected withaconstruct simultaneously expressing an shRNA targeted to LAT and GFP.

DETAILED DESCRIPTION

The engagement of the multi-subunit T-cell receptor (TCR) is rapidlyfollowed by the activation of protein tyrosine kinases (PTKs) thatphosphorylate a number of downstream substrates, of which a prominentexample is LAT, a transmembrane adapter protein. Phosphorylatedtyrosines on LAT serve as docking sites for multiple proteins containingSrc homology 2 domains, including adapters such as Gads and Grb2, whichin turn are associated with other signaling proteins. For example,SLP-76 is recruited to LAT through association with Gads. TheLAT-Gads-SLP-76 complex creates a platform for the recruitment ofnumerous other signaling molecules, including phospholipase C-_(γ)1(PLC-_(γ)1), the Rho family GTPase exchange factor Vav, and theubiquitin ligase Cbl. Thus, TCR engagement induces the formation ofLAT-based signaling complexes that initiate intracellular signalsrequired for T-cell activation.

To ensure an appropriate immune response to antigenic challenge, withoutgenerating an autoimmune response, it is crucial that T-cell activationbe tightly regulated. TCR engagement activates several mechanisms thathave been described to attenuate TCR-mediated signaling, includingligand-induced internalization and degradation of activated signalingmolecules. For example, c-Cbl mediated ubiquitin conjugation to the TCRζchain has been correlated with TCR internalization into endosomalcompartments and the subsequent degradation of the receptor in activatedT cells. In addition, Cbl proteins downregulate PTKs such as Lck, Fyn,and ZAP-70, as well as non-PTK molecules such as the p85 subunit ofphosphatidylinositol 3-kinase and the guanine nucleotide exchange factorVav.

This tightly controlled, short lived response is advantageous during anendogenous immune response, however, when T-cells are administered for achronic disease such as cancer or a viral infection, persistence ofT-cells and a T-cell response is advantageous.

As demonstrated herein, expression of an ubiquitin-deficient LAT inT-cells results in increased signaling through the T-cell receptor ascompared to a cell expressing wild-type LAT. This increased signalingcould result in an increase in T-cell viability by increased cellproliferation or decreased or delayed apoptosis, increased cytokinerelease, or in the case of cytotoxic T cells, enhanced lytic activity onappropriate targets. Increased signaling through the TCR could alsoallow for the use of TCRs having a lower avidity for the target antigen.

While most studies on internalization as a means of signaldownregulation in T cells have focused on the fate of the TCR, resultsfrom studies tracking individual components of TCR-induced microclustersin real time suggest that the fates of the TCR and signaling proteinsdiverge during T-cell activation. In systems using either stimulatoryantibodies or lipid bilayers to model T-cell activation, whereasmicroclusters contain both the TCR and signaling molecules initially,signaling molecules dissociate from the receptor soon thereafter. UponTCR activation, LAT-containing signaling clusters are internalized intovarious distinct intracellular compartments prior to dissipatingrapidly. Expression of versions of c-Cbl defective in the RING fingerdomain, which mediates ubiquitin ligase activity, resulted in severelydecreased internalization of LAT and SLP-76 clusters, decreasedubiquitylation of LAT, and an increase in basal LAT levels, as well aselevated basal and TCR-induced phosphorylated LAT (pLAT) levels. Theinhibition of LAT internalization was also observed in T cells from micelacking c-Cbl. These data are consistent with a model in whichTCR-mediated activation first leads to the rapid formation of signalingcomplexes, after which c-Cbl activity is involved in the internalizationand possible downregulation of a subset of activated signalingmolecules. Given the essential scaffolding role of the adapter proteinLAT in T-cell activation, the regulated internalization of activated LATsignaling complexes may be one efficient strategy by which to controlthe duration and localization of signaling from microclusters and, thus,regulate the kinetics, intensity, and specificity of T-cell signaling.

To further analyze the role of LAT ubiquitylation in TCR signaling,lysines identified as potential ubiquitylation sites in LAT were mutated(K52R, K204R and 2KR which contains both lysine mutations) and theability of LAT to act as a substrate for ubiquitylation was assayed intissue culture cells. Using the immunoprecipitation-western blot methodsdescribed below in the Examples, it was determined that LAT wasubiquitylated primarily on amino acid K52 (see, e.g., FIG. 2B). Asexpected, the 2KR LAT construct in which both K52 and K204 are mutatedto arginines also showed severely decreased ubiquitylation.Ubiquitylation sites in mouse are at amino acids 53 and 121.

It is expected that mutation at the equivalent amino acids in mousewould have the same effect on T cell signaling in mouse cells as themutations in human cells. Further, it is expected that mutation of thelysines to any amino acid that could not be ubiquitylated, i.e., anyamino acid other than cysteine, that did not disrupt protein foldingwould have a similar effect on T cell signaling. Preferably, thesubstitution is a conservative substitution, wherein the basic lysineamino acid is replaced with another basic amino acid, i.e., arginine orhistidine. The K to R substitution is prevents ubiquitination becausethe alpha-carboxyl group of the terminal glycine on ubiquitin forms anisopeptide bond with an (epsilon) amino group in the side chain of alysine residue of the target protein. Thus K is mutated to R to preservethe basic residue which may be important for protein structure, but thissubstitution prevents ubiquitylation. Generation of coding sequence forproteins including point mutations is well within the ability of thoseof skill in the art (see, e.g., Alberts et al., Molecular Biology of theCell, 2^(nd) Edition, c. 1989, Garland Publishing Inc.). Moreover,methods of testing such proteins for activity using any of the methodsprovided herein is routine and well within the ability of those of skillin the art.

Using the 2KR LAT mutant, time to formation and internalization of LATcontaining clusters was determined using established methods (seeBalagopalan et al., c-Cbl-mediated regulation of LAT-nucleated signalingin complexes. Mol. Cell. Bio. 2007; 27:8622-8636, incorporated herein byreference). Briefly, T-cells expressing fluorescently tagged proteins,e.g., LAT-YFP (yellow fluorescent protein) were dropped onto anantibody-coated coverslip maintained in media at 37° C.Receptor-initiated signaling is triggered by the settling of the cellson the coverslip surface. Images were captured using high resolutionmicroscopy.

The results from an experiment using cells expressing either wild-typeLAT-YFP or the 2KR LAT-YFP either alone or in conjunction with 70Z Cbl,a ubiquitin deficient Cbl mutant, are shown in FIG. 3. Expression of thewild-type or mutant LAT-YFP had no effect on the amount of time that LATcontaining clusters could be observed in the cells. This is in contrastto cells expressing a 70Z Cbl in conjunction with each of the LAT-YFPsin which LAT containing clusters were demonstrated to be visible forabout twice as long. These data indicate that the variation inpersistence of LAT containing clusters in response to stimulation of theTCR is not dependent upon ubiquitylation of LAT.

However, 2KR LAT-YFP was found to be more stable in cells than wild-typeLAT-YFP (see FIG. 4A and FIG. 4B). Jurkat E6.1 cells transfected withexpression constructs encoding either mutant or wild-type LAT-YFP weresorted to provide populations with equivalent LAT-YFP levels. Cells werecultured for 24 hours and then total YFP was analyzed. Cells expressingthe 2KR mutant LAT were found to have significantly higher mean YFPlevels. These results demonstrate that LAT lacking ubiquitylation sitesis more stable than wild-type LAT.

To test whether higher protein levels of 2KR LAT-YFP reflected increasedtranscription of this construct, transcript levels were measured byquantitative RT-PCR. Jurkat E6.1 cells were transiently transfected withwild-type LAT-YFP or 2KR LAT-YFP and were evaluated for chimeric LAT-YFPand endogenous LAT-YFP transcript expression. Transcript levels of the□-actin gene were used as a reference. Transcript levels of wild-typeLAT-YFP and 2KR LAT-YFP were not significantly different.

The rate of degradation of wild-type and 2KR-LAT proteins were assayedby pulse chase analysis (FIG. 5A and FIG. 5B). Jurkat JCam2.5 cells thatdo not express endogenous LAT were stably transfected with expressionconstructs encoding either 2KR mutant or wild-type LAT. Cells wereincubated or “pulsed” with S³⁵ labeled methionine and cysteine. Wholecell lysates were prepared at various time-points after the initialpulse and LAT immunoprecipitations were performed. Autoradiographanalysis revealed that the half-life of 2KR LAT was found to be greaterthan 120 minutes, whereas the half-life of wild-type LAT was found to be70 minutes. The availability of more LAT for longer periods of timesuggests a method to provide increased and/or prolonged signaling in Tcells. Treatment of cells with the proteosome inhibitor MG-132 alsoinhibited degradation of LAT, but no inhibition was observed as a resultof treatment of cells with the lysosome protease inhibitor leupeptin(FIG. 5C, FIG. 5D and FIG. 5E), further demonstrating that LATdegradation was ubiquitin and proteosome mediated.

To determine if the persistence of the non-ubiquitylated LAT did in factcorrespond to an increase in persistence of LAT signaling, JurkatJCam2.5 cells lacking endogenous LAT (FIG. 6A, FIG. 6B and FIG. 6C) weretransfected with expression constructs encoding either 2KR mutant orwild-type LAT. Cells were stimulated with CD3 antibody and calciuminflux was monitored using a fluorescent dye. The level and persistenceof T-cell signaling was increased in the cells transfected with the 2KRLAT relative to cells expressing only wild-type LAT. No signaling wasdetected in cells not expressing LAT.

To further confirm an increase in TCR signaling in cells expressing the2KR-LAT, Jurkat JCam2.5 cells transfected with expression constructsencoding either 2KR mutant or wild-type LAT were stimulated with CD3 andassayed for production of CD69, the earliest identified inducible cellsurface glycoproteins as a way to measure T-cell activation throughanother signaling pathway (FIG. 6C). Expression of CD69 was comparablein unstimulated cells expressing either wild-type or 2KR LAT, however,after stimulation with CD3, expression of CD69 was substantially higherin cells expressing 2KR LAT. These results further demonstrate anincrease in TCR signaling in cells expressing a ubiquitin deficient LAT.

To further elucidate the role of LAT ubiquitylation in T cell signaling,endogenous LAT expression was knocked-down in Jurkat E6.1 cells andwild-type or 2KR LAT-YFP were re-expressed in these cells. Westernblotting experiments revealed that endogenous LAT expression wasdramatically reduced in cells transfected with LAT-targeting siRNA.Furthermore, 2KR LAT-YFP was expressed at higher levels than wild-typeLAT-YFP as expected (from results in FIG. 4A AND FIG. 4B). TCR-inducedsignaling outputs such as Ca++ influx, NFAT activation and CD69upregulation were elevated in cells reconstituted with 2KR LAT-YFP ascompared with cells expressing wild-type LAT-YFP (FIG. 7A, FIG. 7B, FIG.7C, FIG. 7D and FIG. 7E). Importantly, comparison of signaling in cellsexpressing equivalent levels of wild-type and 2KR LAT-YFP revealed that2KR LAT-YFP caused more effective T cell signaling on a per moleculebasis as compared with wild-type LAT. Furthermore, the LAT ubiquitinmutant shifted the dose response, so that a lower stimulation wasrequired to trigger a response of the same magnitude. This may be ofbenefit in physiological settings of limited ligand concentrations.

The effects of 2KR expression was tested in non-transformed primaryhuman CD4+ T cells. Endogenous LAT expression was reduced using siRNAtargeting LAT and simultaneously plasmids expressing wild-type LAT-YFPor 2KR LAT-YFP were re-expressed. Transfected cells were stimulated withvarious doses of CD3 and CD28 and evaluated for CD69 upregulation 16hours post-stimulation. Consistent with results obtained in Jurkatcells, enhanced CD69 upregulation was observed in cells expressing 2KRLAT at all doses tested (FIG. 8A, FIG. 8B AND FIG. 8C). Taken together,these results demonstrate a critical role for LAT ubiquitylation inmaintaining normal T cell signaling. In all cell types tested, cellsbearing ubiquitin-deficient LAT were hyperresponsive to stimulationthrough the TCR.

To further analyze the role of LAT expression in T-cell signaling,siRNAs and shRNAs targeted to LAT were designed and transfected intocells. Cells were tested for calcium influx in response to stimulationwith CD3 antibody (FIG. 9A, FIG. 9B and FIG. 9C). All three of thesiRNAs targeted to LAT were able to decrease calcium flux to backgroundlevel in cells (FIG. 9A). shRNA-GFP fusion constructs allowed for thegating of cells based on the expression of GFP in the cells, whichpresumably correlates with the level of shRNA present in the cell andinversely correlates with LAT protein levels. The greater the expressionof GFP, the more substantial the dampening of the calcium influx intothe cells in response to stimulation with CD3 (FIG. 9B and FIG. 9C).These data demonstrate that LAT expression has a dose dependent effecton signaling through the TCR.

The 2KR LAT protein can be used as a therapeutic agent for the treatmentof various diseases and conditions for which a temporally extendedimmune response, beyond that in cells expressing wild-type LAT isdesired. The 2KR LAT protein can be expressed in cells expressing a TCRdirected to the antigen of interest, e.g., a cancer antigen, or apathogenic antigen, e.g., a viral antigen, a parasitic antigen, abacterial antigen, etc. In certain embodiments of the invention, anucleic acid sequence encoding the 2KR protein, or an effective fragmentthereof, is delivered to the T cell, typically in conjunction with theTCR targeted to the antigen of interest. However, in certainembodiments, T cells expressing the TCR of interest can be selected andexpanded.

In an exemplary method, T cells are collected from the subject to betreated and expanded ex vivo under conditions appropriate to allowre-administration of the cells to the subject after transfer of thedesired coding sequences. Methods such as transfection byelectroporation or transduction by adenoviral, adeno-associated viral,retroviral, or lentiviral systems; or other methods and systems thatinclude the use of reagents acceptable for administration to humans arepreferred.

In an alternative embodiment, a nucleic acid encoding a protein foradministration can be administered systemically. Larger doses of nucleicacid would be used for administration systemically as compared todosages for ex vivo administration. Such considerations are wellunderstood by those of skill in the art.

In certain embodiments, cell specific promoters for expression of LATproteins in T-cells would be used. Such promoters include, but are notlimited to, human CD2, distal Lck, and proximal Lck. In otherembodiments, non-tissue specific promoters such as non-tissue specificpromoters including viral promoters such as cytomegalovirus (CMV)promoter, β-actin promoter including the chicken β-actin promoter,phosphoglycerate kinase (PGK) promoter, ubiquitin promoter includinghybrid ubiquitin promoter, and EF-1α promoter can be used.

Other regulatory sequences for inclusion in expression constructsinclude poly-A signal sequences, for example SV40 polyA signalsequences. The inclusion of a splice site (i.e., exon flanked by twointrons) has been demonstrated to be useful to increase gene expressionof proteins from expression constructs.

Enhancers can also be used in the constructs of the invention. Enhancersinclude, but are not limited to enhancer is selected from the groupconsisting of cytomegalovirus (CMV) enhancer, an elongation factor1-alpha enhancer, and liver-specific enhancers.

For viral sequences, the use of viral sequences including invertedterminal repeats, for example in AAV viral vectors can be useful.Certain viral genes can also be useful to assist the virus in evadingthe immune response after administration to the subject.

In certain embodiments of the invention, the viral vectors used arereplication deficient, but contain some of the viral coding sequences toallow for replication of the virus in appropriate cell lines. Thespecific viral genes to be partially or fully deleted from the viralcoding sequence is a matter of choice, as is the specific cell line inwhich the virus is propagated. Such considerations are well known tothose of skill in the art.

Further, viruses with specific tropisms that will cause them to go toefficiently infect liver cells can be selected for use in the method ofthe invention. For example, the AAV8 serotype is known to bepreferentially hepatotrophic (Nakai et al., 2005. J. Virol. 79:214-224).

Compositions and methods for gene delivery to various organs and celltypes in the body are known to those of skill in the art. Suchcompositions and methods are provided, for example in U.S. Pat. Nos.7,459,153; 7,282,199; 7,259,151; 7,041,284; 6,849,454; 6,410,011;6,027,721; and 5,705,151, all of which are incorporated herein byreference. Expression constructs provided in the listed patents and anyother known expression constructs for gene delivery can be used in thecompositions and methods of the invention.

Methods of viral vector design and generation are well known to those ofskill in the art, and methods of preparation of viral vectors can beperformed by any of a number of companies or using routine laboratorymethods. Expression constructs provided herein can be inserted into anyof the exemplary viral vectors listed below.

Gene transfer and nucleic acid therapeutics have been demonstrated totypically be more effective when delivered to the desired site of actionrather than systemically, e.g., by delivering the viral vector ex vivo ,both increasing delivery and transduction efficiency and reducingundesirable systemic effects.

Gene transfer to the liver using AAV vectors for the treatment ofhemophilia B is currently being tested in a phase 1 trial, see, e.g.,clinicaltrials.gov identifier NCT00515710. The study includesintra-hepatic administration of AAV2-hFIX (Factor IX) and secondaryoutcomes for analysis include determining the potential efficacy in eachdose group by measuring biological and physiological activity of thetransgene product. This human trial follows a large number of animalexperiments in which AAV vectors were efficiently delivered to the liverusing AAV2 and AAV8 viral vectors (e.g., Mount et al. Blood. 2002;99:2670-2676; Cardone et al., Hum Mol Genet. 2006; 15:1225-1236; Daly etal., Gene Ther. 2001; 8:1291-1298; McEachern et al. J Gene Med. 2006;8:719-729; Koeberl et al., Gene Ther. 2006; 13:1281-1289; Moscioni etal., Mol Ther. 2006; 14:25-33; Park et al., Exp Mol Med. 2006;38:652-661; Scallan et al. Blood. 2003; 102:2031-2037; Seppen et al. MolTher. 2006; 13:1085-1092; each of which is incorporated by reference)

Many studies have demonstrated that local adminstration to the eyeprovides efficient transduction of cells with viral vectors. In theBainbridge study (NEJM, 358:2231-2239, 2008, incorporated herein byreference), the tgAAG76 vector, a recombinant adeno-associated virusvector of serotype 2 was used for gene delivery. The vector contains thehuman RPE65 coding sequence driven by a 1400-bp fragment of the humanRPE65 promoter and terminated by the bovine growth hormonepolyadenylation site, as described elsewhere.

Additional AAV vectors are provided in the review by Rolling 2004 (GeneTherapy 11: S26-S32, incorporated herein by reference). Hybrid AAV viralvectors, including AAV 2/4 and AAV2/5 vectors are provided, for example,by U.S. Pat. No. 7,172,893 (incorporated herein by reference). Suchhybrid virus particles include a parvovirus capsid and a nucleic acidhaving at least one adeno-associated virus (AAV) serotype 2 invertedterminal repeat packaged in the parvovirus capsid. However, theserotypes of the AAV capsid and said at least one of the AAV invertedterminal repeat are different. For example, a hybrid AAV2/5 virus inwhich a recombinant AAV2 genome (with AAV2 ITRs) is packaged within aAAV Type 5 capsid.

Self-complementary AAV (scAAV) vectors have been developed to circumventrate-limiting second-strand synthesis in single-stranded AAV vectorgenomes and to facilitate robust transgene expression at a minimal dose(Yokoi, 2007. IOVS. 48:3324-3328, incorporated herein by reference).Self-complementary AAV-vectors were demonstrated to provide almostimmediate and robust expression of the reporter gene inserted in thevector. Subretinal injection of 5×10⁸ viral particles (vp) ofscAAV.CMV-GFP resulted in green fluorescent protein (GFP) expression inalmost all retinal pigment epithelial (RPE) cells within the area of thesmall detachment caused by the injection by 3 days and strong, diffuseexpression by 7 days. Expression was strong in all retinal cell layersby days 14 and 28. In contrast, 3 days after subretinal injection of5×10⁸ vp of single stranded (ss)AAV.CMV-GFP, GFP expression wasdetectable in few RPE cells. Moreover, the ssAAV vector required 14 daysfor the attainment of expression levels comparable to those observedusing scAAV at day 3. Expression in photoreceptors was not detectableuntil day 28 using the ssAAV vector. The use of the scAAV vector in thegene delivery methods of the invention can allow for prompt and robustexpression from the expression construct. Moreover, the higher level ofexpression from the scAAV viral vectors can allow for delivery to of theviral particles intravitreally rather than subretinally.

Various recombinant AAV viral vectors have been designed including oneor more mutations in capsid proteins or other viral proteins. It isunderstood that the use of such modified AAV viral vectors falls withinthe scope of the instant invention.

Kota et al. (Cell, 137: 1005-1017, 2009, incorporated herein byreference) demonstrated efficient delivery of an AAV expression vectorcontaining an shRNA targeted to miR-26a in vivo in a model of rathepatocellular carcinoma.

Adenoviral vectors have also been demonstrated to be useful for genedelivery. For example, Mori et al (2002. IOVS, 43:1610-1615,incorporated herein by reference) discloses the use of an adenoviralvector that is an E-1 deleted, partially E-3 deleted type 5 Ad in whichthe transgene (green fluorescent protein) is driven by a CMV promoter.Peak expression levels were demonstrated upon injection of 10⁷ to 10⁸viral particles, with subretinal injection providing higher levels ofexpression than intravitreal injection.

Efficient non-viral ocular gene transfer was demonstrated by Farjo etal. (2006, PLoS 1:e38, incorporated herein by reference) who usedcompacted DNA nanoparticles as a system for non-viral gene transfer toocular tissues. As a proof of concept, the pZEEGFP5.1 (5,147 bp)expression construct that encodes the enhanced green fluorescent protein(GFP) cDNA transcriptionally-controlled by the CMV immediate-earlypromoter and enhancer was used. DNA nanoparticles were formulated bymixing plasmid DNA with CK30PEG10K, a 30-mer lysine peptide with anN-terminal cysteine that is conjugated via a maleimide linkage to 10 kDapolyethylene glycol using known methods. Nanoparticles were concentratedup to 4 mg/ml of DNA in saline. The compacted DNA was delivered at a 0.6μg dose to the vitreal cavity. GFP expression was observed in the lens,retina, and pigment epithelium/choroid/sclera by PCR and microscopy.

Further, a number of patents have been issued for methods of ocular genetransfer including, but not limited to, U.S. Pat. No. 7,144,870 whichprovides methods of hyaluronic acid mediated adenoviral transduction;U.S. Pat. Nos. 7,122,181 and 6,555,107 which provide lentiviral vectorsand their use to mediate ocular gene delivery; U.S. Pat. No. 6,106,826which provides herpes simplex viral vectors and their use to mediateocular gene delivery; and U.S. Pat. No. 5,770,580 which provides DNAexpression vectors and their use to mediate ocular gene delivery. Eachof these patents is incorporated herein by reference.

Hepatic gene delivery has also been demonstrated in a number of studies.For example, self-complementary adeno-associated virus vectorscontaining a novel liver-specific human factor IX expression cassettewere found to enable highly efficient transduction of murine andnonhuman primate liver (Nathwani et al. Blood. 2006 Apr. 1;107:2653-61). An AAV-2 genome encoding the hflX gene was cross-packagedinto capsids of AAV types 1 to 6 using efficient, large-scale technologyfor particle production and purification. In immunocompetent mice, theresultant vector particles expressed high hFIX levels ranging from 36%(AAV-4) to more than 2000% of normal (AAV-1, -2, and -6), which wouldexceed curative levels in patients with hemophilia. (Grimm et al.,Blood. 2003 Oct. 1; 102:2412-9).

Further, a number of patents have been issued for methods of hepaticgene or nucleic acid transfer including, but not limited to U.S. Pat.Nos. 7,615,537 and 7,351,813 which provide methods for expression ofclotting factor in the liver; U.S. Pat. No. 7,528,118 which providesmethods for delivery of siRNA to liver to reduce expression of ApoB;U.S. Pat. No. 7,498,017 provides a cationic poly cyclicimidazolinium-containing compound for condensing nucleic acid fordelivery to a cell, including a liver cell; and U.S. Pat. No. 6,967,018for delivery of AAV-1, 2, or 5 vectors for the expression ofadiponectin. Each of these patents related to hepatic gene or nucleicacid transfer is incorporated herein by reference.

Such viral vectors and methods can be used for the delivery of nucleicacids encoding modified LAT proteins to T cells.

Self-complementary Adenoviral Vectors

Under normal circumstances, AAV packages a single-stranded DNA moleculeof up to 4800 nucleotides in length. Following infection of cells by thevirus, the intrinsic molecular machinery of the cell is required forconversion of single-stranded DNA into double stranded form. Thedouble-stranded form is then capable of being transcribed, therebyallowing expression of the delivered gene to commence. It has been shownin a number of cell and tissue types that second strand synthesis of DNAby the host cell is the rate-limiting step in expression. By virtue ofalready being packaged as a double stranded DNA molecule,self-complementary AAV (scAAV) bypasses this step, thereby greatlyreducing the time to onset of gene expression.

Self-complementary AAV is generated through the use of vector plasmidwith a mutation in one of the terminal resolution sequences of the AAVvirus. This mutation leads to the packaging of a self-complementary,double-stranded DNA molecule covalently linked at one end. Vectorgenomes are required to be approximately half genome size (2.4 KB) inorder to package effectively in the normal AAV capsid. Because of thissize limitation, large promoters are unsuitable for use with scAAV. Mostbroad applications to date have used the cytomegalovirus immediate earlypromoter (CMV) alone for driving transgene expression. A long acting,ubiquitous promoter of small size is useful in a scAAV system.

Xu et al (Mol. Ther. 11: 523-530, 2005, incorporated herein byreference) have demonstrated efficient shRNA expression in mammaliancancer cells after delivery using an scAAV vector. U.S. Pat. No.7,465,583 teaches delivery of nucleic acid to various cell types usingscAAV vectors (incorporated herein by reference).

Gene Transfer Using Plasmid DNA

Delivery of plasmid DNA has been demonstrated to be an efficient methodof gene transfer in vivo (Yoshino et al., 2006, and Budker et al, 1996;Zhang et al., 1997; each incorporated herein by reference). The methodsprovided herein include gene transfer ex vivo. In the methods, thenucleic acid is delivered directly to the tissue. Therefore, the nucleicacid need not be packaged or modified to direct it to the appropriatetissue. Moreover, as the nucleic acid is delivered to the cells over ashort time period, the nucleic acid is far less susceptible to theeffects of nucleases than a nucleic acid delivered systemically. Theinvention provides expression of a coding sequence in naked DNA whichincludes DNA not enclosed in a viral capsid, but can include othercompounds to promote cellular uptake and/or to increase the stability ofthe DNA. Such compounds are preferably safe for use in humans and suchconsiderations are well known to those of skill in the art. Typically,naked DNA is in the form of plasmid DNA, such as supercoiled plasmid DNAto provide some protection against nucleases that may be present. Genetransfer using plasmid DNA can also include the use of plasmid DNA thathas been cut, for example, with a restriction enzyme, to provide alinear DNA molecule. Gene transfer using plasmid DNA may be beneficialas it may overcome the obstacle of immune response to viral capsidproteins.

EXAMPLE 1 Materials and Methods

Reagents: Human anti-CD3ε (UCHT or HIT3a) monoclonal antibodies werepurchased from Pharmingen and were used to coat coverslips. Thefollowing antibodies were used for western blotting andimmunoprecipitation: Anti-HA-HRP (Roche), mouse anti-LAT (Upstate),mouse anti-β actin (SIGMA), rabbit anti-pLAT191 (Invitrogen), mouseanti-pY clone 4G10 (Millipore). APC-conjugated CD69 antibody was from BDPharmingen. Indo-1 AM was from Invitrogen. OKT3 binding the human CD3-εchain was used to trigger T cell activation.

COS-7 cell transfection, immunoprecipitation and immunoblotting: COS-7cells were transfected using Lipofectamine® Plus reagent as recommendedby the manufacturer (SIGMA®). Briefly, 60 mm dishes were seeded withcells and 70% confluent cell cultures were used for transfection. Cellswere co-transfected with WT, K52, K204 or 2KR LAT (0.5 μg) and HA-Ub(0.5 μg). 24 hours post-transfection, cells were lysed in ice-coldNonidet®-40 lysis buffer (50 mM Tris pH 7.4; 150 mM NaCl; 5 mM EDTA; 5mM EGTA; 50 mM NaF; 1% NP-40), and cellular lysates were subjected toimmunoprecipitation using mouse anti-LAT monoclonal antibody (Upstate).Protein A/G Plus-Agarose beads (Santa Cruz Biotechnology) were used forimmunoprecipitation. Protein samples were resolved bysodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE),transferred to nitrocellulose membrane and immunoblotted withappropriate primary antibodies followed by enhanced chemiluminescence(Upstate).

Cell culture and transfection of Jurkat cells: Jurkat E6.1 cells andLAT-deficient , Jurkat cells have been described previously (Zhang etal., 2000, incorporated herein by reference). All Jurkat cells werecultured in RPMI 1640 supplemented with 10% fetal bovine serum andantibiotics. For protein expression, Jurkat cells were transfected with5-25 μg plasmid DNA using the electroporation system, solution T, andprogram H-10 from LONZA. Transiently transfected cells were harvested oranalyzed 24-48 hrs. post-transfection.

Confocal microscopy and image processing to calculate lifetime of LATclusters: Spreading assays were performed as described previously(Bunnell et al., 2002). Briefly chambered coverslips (LabTek) werecoated overnight at 4° C. with the stimulatory antibody human anti-CD3ε(HIT3a or UCHT at 10 μg/ml). Jurkat E6.1 cells transfected with YFP-andCFP-tagged constructs were plated onto coated coverslips containingimaging buffer (RPMI 1640 without phenol red, 10% fetal calf serum, 20mM Hepes). Movement of fluorescent proteins in live cells were observedwith a Zeiss® Axiovert 200 microscope equipped with a Perkin-Elmer®Ultraview spinning disc confocal system (Perkin Elmer). Images werecaptured with an Orca-ERII CCD camera (Hamamatsu). A hot air blower andan objective warmer were used to maintain live samples at 37° C.

IPLab 3.6 (Scanalytics® Inc.) was used for most image processing. Movieswere prepared from z-stacks by making a maximum intensity projection ofa given time point and then making a sequence of all the projections.Kymographs were made from regions of interest (ROI) drawn around movingclusters of interest and the movement of clusters was analyzed usingIPLab3.6. Graphs were prepared with Microsoft Excel (Microsoft®).

Pulse-chase analysis: Jurkat Jcam2.5 cells reconstituted with wild-typeor 2KR LAT (1×10⁷) were washed once with PBS and incubated for 30 min at37° C. under 5% CO₂ in methionine-deficient RPMI 1640 medium (Sigma).The cells were pulse-labeled with [³⁵S]methionine-[³⁵S]cysteine mix (GEHealthcare® for 20 min at 37° C. under 5% CO₂ and washed twice in PBS.Equal portions were added to 500 ml of RPMI-FBS for each time point ofthe chase period and incubated at 37° C. At the indicated time points,cells were harvested and lysed in ice-cold lysis buffer containing 1%Brij, 1% n-Octyl-D-glucoside, 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mMethylenediaminetetraacetic acid, 1 mM Na₃VO₄ and complete proteaseinhibitor tablets (Roche®). Protein A/G Plus-Agarose beads (Santa CruzBiotechnology) were used for immunoprecipitation. Protein samples wereresolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis(SDS-PAGE), transferred to nitrocellulose membrane, and placed on aphosphor imager for detection of labeled protein.

Measurement of Ca⁺⁺ influx: Cells were incubated with 5 μM Indo-1-AM(Molecular Probes®) and 0.5 mM probenecid (Sigma( ®) in RPMI 1640 mediumat 37° C. for 45 min. The cells were washed with RPMI 1640, resuspendedin imaging buffer containing 0.5 mM probenecid, and kept at roomtemperature for 30-45 min. The cells were incubated at 37° C. for 5 minbefore measurements, stimulated with 50 ng/ml OKT3 antibody and analyzedusing the LSR II (BD Biosciences). The data were processed using TreeStar FlowJo® software.

siRNA and shRNA mediated depletion of LAT levels: The small interferingRNA (siRNA) corresponding to human LAT and the control nontargetingsiRNA pool were purchased from Dharmacon Inc. The SMARTpool duplexes forhuman LAT were designed to target the following mRNA sequences:SMARTpool duplex 1, GCACAUCCUCAGAUAGUUU (SEQ ID NO: 5) which targetsnucleotides 113-131 (from +1 at the ATG); duplex 2, CAAACGGCCUCACACGGUU(SEQ ID NO: 6) which targets nucleotides 153-171; duplex 3,GGACGACUAUCACAACCCA (SEQ ID NO: 7) which targets nucleotides 372-390;and duplex 4, CCAACAGUGUGGCGAGCUA (SEQ ID NO: 8) which targetsnucleotides 311-329. Briefly, Jurkat E6.1 cells were transfected withcontrol siRNA or siRNA for LAT (100 μm/5×10⁶ cells) by using a LONZA®electroporator, solution T, and program H-10.pSUPER.neo.GFP was obtainedfrom OligoEngine®.

The shRNA for LAT were designed to target the following mRNA sequences(shl: CCAACAGUGUGGCGAGCUA (SEQ ID NO: 8) that corresponds to nucleotides311-329 in the LAT coding sequence with ATG as+1, sh5:CGUGUAGGAGUCUAUCAAA (SEQ ID NO: 9) that corresponds to nucleotides118-136 in LAT 5′ UTR). Briefly, Jurkat E6.1 cells were transfected withcontrol shRNA or shRNA for LAT (25 μg/10×10⁶ cells) by using a LONZA®electroporator, solution T, and program H-10. Cells were analyzed 48hrs. post-transfection.

QPCR Total RNA was prepared on transfected cells using Trizol(Invitrogen, Carlsbad, Calif.). For each sample, 1 μg RNA was reversetranscribed into cDNA with oligo d(T) and the AffinityScript™ QPCR cDNASynthesis Kit (Agilent, Santa Clara, Calif.). For real-time,quantitative PCR, the same sense primer was used for both endogenous andtransfected LAT: 5′ GGCAGCCGGGAGTATGTGAATGTGTCCCAG 3′ (SEQ ID NO: 10).Endogenous LAT was detected by adding an antisense primer from the 3′UTR not present in the transfected construct: 5′ GGCGTCCTGCCCTTGCTCCAGCC3′ (SEQ ID NO: 11). Transfected LAT was detected by adding an antisenseprimer from the YFP coding sequence: 5′ GTGGTGCCCATCCTGGTCGAGCTGGACGGC3′ (SEQ ID NO: 12). The primers and cDNA were combined with Brilliant®II QRT-PCR AffinityScript Master Mix containing SYBR green (Agilent,Santa Clara, Calif.), and qper reactions were run and analyzed on theMx3000P (Agilent, Santa Clara, Calif.). β-actin was used fornormalization: Sense: 5′ CCACTGGCATCGTGATGGAC 3′ (SEQ ID NO: 13)Antisense: 5′ GCGGATGTCCACGTCACACT 3′ (SEQ ID NO: 14). Relative levelswere quantitated using the DDCT method.

Flow cytometry assays: E6.1 Jurkat cells were transfected with wild-typeor 2KR LAT-YFP constructs. Twenty four hours following transfectioncells were analyzed and sorted for similar levels of expression using aBeckton-Dickinson® FACS Vantage SE flow cytometer (Beckton-Dickinson®Inc.). Sorted cells were cultured for 24 hrs. and analyzed again forexpression levels. The data were analyzed in Tree Star FlowJo®software.Mean LAT-YFP levels (+s.e.m.) were measured.

Functional assays: For measurement of Ca⁺⁺ influx, cells were incubatedwith 5 M Indo-1-AM (Molecular Probes®) and 0.5 mM probenecid (Sigma®) inRPMI 1640 medium at 37° C. for 45 min. The cells were washed with RPMI1640, resuspended in imaging buffer containing 0.5 mM probenecid, andkept at room temperature for 30-45 min. The cells were incubated at 37°C. for 5 min before measurements, stimulated with various doses ofsoluble OKT3 antibody and analyzed using the LSR II (BD Biosciences).The data were processed using Tree Star FlowJo® software.

For measurement of surface CD69 levels in Jurkat E6.1 or JCam2.5 cells,1×10⁶ cells were stimulated in solution with various doses of CD3(OKT3). Isolated CD4+ PBMCs were stimulated on various doses ofplatebound CD3 (OKT3) and CD28 in a 96 well round bottom plate. Sixteenhours post-stimulation, cells were stained with APC-conjugated CD69 (BDPharmingen), and surface expression was analyzed on a FACSCaliburcytometer (BD Biosciences). The data were processed using Tree StarFlowJo software.

For luciferase assays, cells were simultaneously transfected with siRNAtargeting LAT or control siRNA and YFP, LAT-YFP or 2KR LAT-YFP alongwith 4 μg of a NF-AT luciferase reporter plasmid and 1 μg/ml of acontrol β-galactosidase expression vector. 48 hours post-transfection,cells were stimulated with various dilutions of OKT3 in solution. After6 h at 37° C., cells were washed with PBS and lysed in 50 μl reporterlysis buffer from the Luciferase assay system kit (Promega) andclarified by centrifugation. The supernatant was then analyzed in thereporter assay according to the manufacturer's protocol and read on anEG and G Berthold Microplate Luminometer LB96V (EG and G Berthold). Forβ-galactosidase activity, plates were read on Versamax microplate reader(Molecular Devices) 30 min after the addition of the relevant reagent.Luciferase activity was normalized to internal β-galactosidase controls.

siRNA mediated depletion of LAT levels and re-expression of LAT: Thesmall interfering RNA (siRNA) corresponding to human LAT and the controlnontargeting siRNA pool were purchased from Dharmacon Inc. The SMARTpoolduplexes for human LAT were designed to target the following mRNAsequences: SMARTpool duplex 4, CCAACAGUGUGGCGAGCUA which targetsnucleotides 311-329. Briefly, Jurkat E6.1 cells were transfected withcontrol siRNA or siRNA for LAT (100 μm/5×10⁶ cells) by using an LONZA®electroporator, solution T, and program II-10. Cells were analyzed 48hrs. post-transfection. For re-expression LAT sequences corresponding to311-329 were altered by site-directed mutagenesis to render re-expressedLAT resistant to targeting siRNA.

Primary human PBMCs culture and transfection PBMCs from healthy donorswere isolated by Ficoll-Hypaque density gradient centrifugation. Human Thelper cells (i.e. CD4+) were negatively isolated from fresh PBMCs usingthe CD4+ T cells negative purification kit according to manufacturer'sinstructions (Stem Cell Technologies). After isolation, CD4+ T cellswere cultured in complete RPMI medium containing 10% fetal bovine serumin the presence of 5 μg/ml PHA (Sigma) and 20 units/ml of recombinanthuman IL-2 for 24 hrs. at 37 ° C. under a 5% CO₂ atmosphere. After 2washes, the cells were then maintained for 5-6 days in exponentialgrowth phase on RPMI complete medium containing 20 units/ml human IL-2.After washing and IL-2 starvation for 24 hrs., the above describedsiRNAs and plasmid DNAs were introduced into cells by electroporationusing the LONZA nucleofector 96-well shuttle system for human T cellsand program E0-115. Cells were evaluated 24 hrs after transfection.

EXAMPLE 2 Human LAT is Ubiquitylated at Amino Acid 52

LAT contains a small extracellular domain, a single transmembranespanning region and a long intracellular region with no apparentintrinsic enzyme activity or commonly described protein-proteininteraction domains (FIG. 2A). The intracellular domain of LAT containsnine tyrosines of which five are phosphorylated (Y127, Y132, Y171, Y191,Y226) (Zhu, Jansen, Zhang J I 2003, Paz 2001), and two membrane proximalcysteine residues (C26 and C29) that are subject to posttranslationalpalmitoylation (Zhang 1998). LAT amino acid sequence also reveals twolysines (K52 and K204 in human LAT) that might serve as potential sitesfor ubiquitylation. Both LAT lysines were mutated either individually orin combination, and the potential ubiquitylation of these LAT proteinswas evaluated. COS-7 cells were transfected with HA-tagged ubiquitin andwild-type (WT) LAT or LAT mutated on lysines, followed byimmunoprecipitation of LAT and anti-HA western blotting. Consistent withpreviously published studies that presented evidence for LATubiquitylation (Brignatz 2005, Balagopalan 2007), immunoprecipitation ofLAT resulted in the co-precipitation of ubiquitylated bands (FIG. 2B).Strikingly, while the LAT K204R mutant displayed ubiquitylation levelssimilar to wild-type LAT (FIG. 2B, compare lanes 2 and 4), the LAT K52Rmutant immunoprecipitates showed greatly decreased anti-HA reactivity(FIG. 2B, lane 3). Not surprisingly, the LAT 2KR mutant in which bothLAT K52 and K204 are mutated also showed decreased ubiquitylation. Thedecreased HA reactivity is not due to a decrease in levels of expressionsince the LAT K52R and LAT 2KR mutants were consistently expressed atlevels equal to or higher than the wild-type and K204R constructs (FIG.2B, lower panel). These data indicate that LAT is predominantlyubiquitylated on K52. For the remainder of the experiments in this studywe used the LAT 2KR mutant in which both lysines 52 and 204 weremutated.

EXAMPLE 3 Ubiquitin-Defective LAT is Internalized at Rates Comparable toWild-Type LAT

To evaluate whether LAT ubiquitylation is required for LATinternalization, we assessed dynamics of wild-type and 2KR LAT. To thisend, we tagged wild-type and 2KR LAT with a YFP tag at the carboxyterminus. Jurkat E6.1 cell lines were transfected with either wild-typeLAT-YFP or 2KR LAT-YFP and trafficking of the fluorescent LAT constructswas evaluated. Both wild-type and 2KR LAT-YFP were recruited rapidly tosignaling clusters in Jurkat E6.1 cells. High-speed microscopic analysisof activated cells in real time revealed that both wild-type LAT-YFP and2KR LAT-YFP clusters dissipated soon after cluster formation in JurkatE6.1 cells (FIG. 3). Similar dynamics of LAT-YFP clusters were observedin Jukat JCam2.5 cells that lack endogenous LAT. These data indicatethat under conditions of severely reduced ubiquitylation, LATinternalization proceeds at regular rates, suggesting thatubiquitylation of LAT is not required for LAT internalization.Alternatively, the residual ubiquitylation of the 2KR LAT mutant in theabsence of major ubiquitylation sites may be sufficient for LATinternalization. We have previously demonstrated that c-Cbl activity isrequired for movement of LAT clusters (Balagopalan et al., 2007).

To examine the effect of c-Cbl expression on 2KR LAT dynamics in livingcells, we transfected Jurkat E6.1 cells expressing wild-type or 2KRLAT-YFP, with 70Z/3 Cbl-CFP, an oncogenic, dominant negative version ofc-Cbl with a 17 amino acid internal deletion into the RING finger domainthat abrogates ubiquitin ligase activity (Andoniou, C. E., et al, 2000.Mol. Cell. Biol. 20:851-867). As shown in FIG. 3, in cells expressing70Z/3 Cbl-CFP, both wild-type and 2KR LAT clusters persisted forextended periods of time. Thus movement of ubiquitin-defective LAT isregulated by c-Cbl activity. Taken together, these results suggest that70Z/3 Cbl causes persistence of LAT complexes due to defectiveubiquitylation of proteins beside LAT. These proteins could potentiallybe other signaling molecules in the LAT-nucleated signaling complex.Alternatively, endocytic adapter proteins may be the targets ofubiquitylation.

EXAMPLE 4 2KR LAT Levels are Higher than Wild-Type LAT Levels inTransiently Transfected Cells

Initially, ubiquitylation was described as the process that labelsproteins for degradation (Hershko and Ciechanover, 1998). To testwhether LAT was regulated in a similar manner, equal amounts wild-typeand 2KR LAT-YFP DNA were transiently transfected into E6.1 Jurkat Tcells and YFP levels monitored by flow cytometry. 24 hours aftertransfection, levels of 2KR LAT-YFP were significantly higher thanwild-type LAT-YFP. To control for differences in transfectionefficiency, cells expressing similar levels of YFP-tagged proteins weresorted. Flow analysis on cells cultured for 24 hours post-sortingrevealed that mean 2KR LAT-YFP levels were increased to nearly two-foldhigher than wild-type LAT-YFP (FIG. 4A). Higher intracellular proteinlevels of LAT containing the lysine mutations could reflect increasedtranscription of the 2KR LAT-YFP construct or increased stability of 2KRLAT-YFP protein. To test the first possibility, relative transcriptabundance was evaluated by quantitative RT-PCR. cDNA was prepared fromE6.1 cells transiently transfected with wild-type LAT-YFP or 2KRLAT-YFP. Real-time quantitative PCR was performed on both samples forchimeric LAT-YFP and endogenous LAT transcript expression. Transcriptlevels of the β-actin gene were used as a reference. In these samples,the relative quantification of the wild-type versus the chimeric 2KRLAT-YFP transcripts revealed no significant differences (FIG. 4B). Thelack of correlation between transcript and protein levels is suggestedto be the consequence of the involvement of post-transcriptionalregulations such as protein degradation.

EXAMPLE 5 Mutation of LAT Lysines Delays LAT Degradation

The data in FIG. 4A and FIG. 4B indicate that 2KR LAT is more stable andresistant to degradation than wild-type LAT. To test this hypothesisdirectly, pulse-chase analysis was performed on Jurkat JCam2.5 cellsthat lack endogenous LAT, but stably express either wild-type or 2KRLAT. Briefly, cells were incubated in medium that contained ³⁵S-labeledmethionine and cysteine. Whole cell lysates were prepared at varioustime-points after the initial pulse and LAT immunoprecipitations wereperformed. Immunoadsorbed proteins were subjected to SDS-PAGE andanalyzed by autoradiography (FIG. 5A). The band above the 36 kDastandard is LAT. The band is absent in LAT-deficient JCam2.5 cells. Toquantitate the amount of labeled LAT recovered at each time-point in thechase, the density of the LAT band on autoradiographs was measured byscanning densitometry. The density of the LAT band decreased with time,indicating that the amount of LAT recovered from the lysates decreasedduring the chase, and likely represents intracellular LAT degradation.Recovery of labeled LAT at 30 minutes, 1 hour and 2 hours was quantifiedin 4 separate experiments. Based on these data the intracellularhalf-life of LAT appears to be 70 minutes. In contrast, even at the120-minute time-point, more than half of 2KR LAT persisted,demonstrating a delay in the degradation of the mutant protein (FIG.5C). Of note, the lysine mutations did not completely block steady statedegradation indicating that other mechanisms of protein degradation mayexist for LAT or alternatively, residual ubiquitylation of the lysinemutant drives degradation. Nonetheless, the 2KR mutation afforded LATsignificant protection from degradation.

Protein degradation occurs through two main cellular routes: theubiquitin-proteasome and the autophagy-lysosome pathways (Knecht,Aguado, Saez Cell. Mol Life Sci 2009). As an initial approach todetermine which pathway mediates steady state degradation of LAT, cellswere preincubated with proteasome (MG-132) or lysosome (leupeptin)inhibitors and subsequently followed by pulse-chase. While degradationof LAT was observed without proteasome inhibitors, its turnover wassignificantly halted in their presence, revealing that LAT steady statedegradation is regulated by the proteasome. In contrast lysosomalinhibition did not have an effect on LAT degradation kinetics FIG. 5Band FIG. 5D.

Given these results, we reasoned that proteasomal degradation ofwild-type LAT in unstimulated cells could explain the differences inexpression levels seen between wild-type and 2KR LAT in FIG. 4A and FIG.4B. To test this hypothesis, wild-type and 2KR LAT-YFP expressing cellswere treated with the proteasomal inhibitor MG-132. Indeed, MG-132treatment shifted wild-type LAT-YFP expression to levels closer to thatof 2KR LAT-YFP expression (FIG. 5E). However, the presence of theproteasome inhibitor also increased the amount of the 2KR mutantobserved, consistent with the observation that the lysine mutations donot completely block steady state LAT degradation.

EXAMPLE 6 Ubiquitylation Defective LAT Mutant Exhibits EnhancedSignaling Downstream of the TCR

Addition of ubiquitin moieties on signaling proteins may serve as ameans to regulate the degree and duration of cell activation (Haglund,K. & Dikic, I. EMBO J. 24, 2005). To investigate whether increasedstability of the LAT 2KR mutant in cells correlates with increased orprolonged signaling by this mutant, signaling assays were performed incells expressing wild-type or 2KR LAT. JCam2.5 cells lacking endogenousLAT were reconstituted with wild-type or 2KR LAT expressed at variouslevels (FIG. 6A). First, CD3-dependent cytosolic Ca⁺⁺ flux wasevaluated. As reported previously, Jurkat JCam2.5 cells do not displayan increase in cytosolic Ca⁺⁺ levels upon CD3 stimulation (Finco 1998,FIG. 6B). Reconstitution of these cells with wild-type LAT led tomeasurable Ca⁺⁺ flux in all cell lines tested. In comparison, allJCam2.5 cell lines reconstituted with 2KR LAT displayed considerablyhigher levels of cytosolic Ca⁺⁺ levels in response to stimulation withanti-CD3ε antibodies.

To identify other indicators of TCR signaling in these cells, CD69levels were measured. CD69 is the one of the first glycoproteinsupregulated on the surface of T cells upon TCR stimulation and is knownto be dependent on Ras activation. JCam2.5 cells stably transfected withwild-type or 2KR LAT were stimulated with anti-CD3ε antibodies. Sixteenhours post-stimulation, surface CD69 levels were measured by flowcytometry. Prior to stimulation, CD69 levels appeared to be marginallyhigher in cells containing 2KR LAT. However, upon CD3 stimulation, moreprofound differences in CD69 expression were observed. Cells expressing2KR LAT had significantly higher levels of CD69 as compared with cellsexpressing wild-type LAT (FIG. 6C). Together, these data demonstratethat signaling pathways downstream of the TCR are enhanced in cells thatexpress ubiquitin-defective 2KR LAT.

An observation apparent from the data in FIG. 6A is that in JCam2.5 celllines stably expressing wild-type or mutant LAT, 2KR levels were higherin all cell lines examined. This is probably due to enhanced stabilityof the lysine mutant protein as demonstrated in FIG. 4A and FIG. 4B.Therefore it was not possible to determine whether the increasedbiologic signaling by LAT mutated on lysines was due to higher proteinlevels in the 2KR reconstituted JCam2.5 cells or due to increasedsignaling properties of the 2KR LAT mutant per se. To address thisissue, JCam2.5 cells were transfected with expression constructs for theexpression of YFP-tagged wild-type or 2KR LAT. We reasoned that gatingon equivalent levels of expression of YFP tagged proteins would enableus to evaluate signaling in cells expressing equal levels of wild-typeor mutant LAT. However, transient expression of YFP-tagged proteins inJCam2.5 cells, at levels no more than two-fold higher than endogenousLAT expression in E6.1 cells, did not reconstitute CD3-stimulatedsignaling. To circumvent these issues, a knock-down re-expression systemwas employed in Jurkat E6.1 cells as described below.

EXAMPLE 7 CD69 Level Upregulation Mediated by TCR Activation is Higherin Cells Expressing Ubiquitin-Defective LAT

RNA-mediated interference was employed to genetically silence endogenousLAT expression in Jurkat E6.1 cells. Simultaneously, either YFP,wild-type or 2KR LAT-YFP was re-expressed in these cells. 48 hours aftertransfection, whole cell lysates were prepared and subject toelectropheresis and immunoblotting for LAT. As shown in FIG. 7A,expression of siRNA targeting LAT dramatically reduced endogenous LATexpression, in comparison to LAT expression in Jurkat E6.1 cells orcontrol siRNA transfected cells. Fluorescence activated cell sorting(FACS) analysis of the YFP-tagged proteins at 48 hours showed higherlevels of 2KR LAT-YFP expression as expected (FIG. 7B). However, the YFPtag enabled us to gate on cells expressing equal amounts of the YFP tag(Gate B), corresponding to equivalent levels of LAT. To test theconsequence of disruption of LAT ubiquitylation for signaling events,TCR-induced Ca⁺⁺ influx was examined at three different concentrationsof CD3 stimulation (FIG. 7C). Transfection of LAT targeting siRNA showedreduced Ca⁺⁺ flux as compared with control siRNA at all threeconcentrations. At 0.025 ug/ml and 0.012 ug/ml anti-CD3 a slight Ca⁺⁺flux remained, but no detectable Ca⁺⁺ flux occurred at 0.006 ug/ml,indicating that endogenous LAT no longer contributed to cytosolic Ca⁺⁺flux at this stimulation dose. In comparison, expression of wild-typeLAT-YFP showed similar levels of Ca⁺⁺ flux as control siRNA transfectedcells at all concentrations tested. Strikingly, LAT depleted cellsreconstituted with 2KR LAT-YFP showed increased cytosolic flux at allCD3 doses. Notably, the effect of mutations of LAT lysines was greaterat the lower abundance of soluble anti-CD3 than at the higherconcentrations. This suggests that LAT ubiquitylation has a moreprominent role in regulation of TCR-mediated signaling under limitingstimulatory conditions.

Increases in intracellular Ca⁺⁺ concentrations upon TCR engagementcontrols various signaling pathways, importantly including activation ofthe transcription factor NFAT. Therefore the LAT expressing cells weresubjected to NFAT luciferase assays. Under all stimulation conditionstested, LAT-depleted cells reconstituted with 2KR LAT showed elevatedsignaling compared with cells reconstituted with its wild-typecounterpart (FIG. 7D). We also checked for other indicators of TCRsignaling such as CD69 upregulation. Anti-CD3 induced CD69 upregulationwas also enhanced at all doses of anti-CD3ε antibody in cellsreconstituted with 2KR LAT (FIG. 7E). Importantly, we evaluatedsignaling output on cells expressing equivalent levels of wild-type and2KR LAT-YFP in the above-described functional assays evaluating Ca⁺⁺influx and CD69 upregulation. These data allow us to conclude that 2KRLAT possesses more potent signaling properties and can cause T cellactivation more effectively on a per molecule basis as compared withwild-type LAT.

EXAMPLE 8 Evaluation of TCR Signaling in LAT Knockdown CellsReconstituted with Wild-Type or 2KR Mutant LAT

To confirm that the effects of 2KR expression occurred innon-transformed cells, we performed experiments in primary human Tcells. CD4⁺ T cells were isolated from freshly isolated PBMCs of healthydonors. CD4⁺ cells were transfected with control siRNA or LAT targetingsiRNA and simultaneously with plasmids expressing YFP, wild-type LAT-YFPor 2KR LAT-YFP as indicated. Similar to the experiments performed inJurkat cells, 2KR LAT expression levels were consistently higher thanwild-type LAT (FIG. 8C). Western blot analysis of lysates from sortedYFP-positive cells was performed to assess both the efficiency of thesiRNA knockdown and levels of re-expressed wild-type and 2KR LAT-YFP. Asshown in FIG. 8A, a knockdown of 35% of endogenous LAT was achieved inthese cells.

Although not as efficient as LAT knockdown in Jurkat E6.1 cells, thefunctional effects of 2KR LAT expression were tested by gating on YFPexpressing cells. Transfected cells were incubated with variousconcentrations of anti-CD3 and anti-CD28 antibodies and evaluated forCD69 upregulation at 16 hours post-stimulation. Of note, the doses ofCD3 had to be increased to see robust CD69 upregulation in primarycells, as compared with the doses used in Jurkat cells. Nevertheless,consistent with observations made in Jurkat cells, we saw enhanced CD69upregulation in cells expressing 2KR LAT at all concentrations tested(FIG. 8B). Interestingly, the differences between 2KR LAT, wild-type LATand cells in which LAT was depleted was most apparent at lower doses ofstimulation, in agreement with our conclusion that LAT ubiquitylationplays a more significant role in TCR activation under limitingstimulatory conditions. Taken together, these data support theconclusion that LAT is targeted by ubiquitylation within lysines andthat these events coordinately downregulate LAT-dependent TCR signalingevents.

EXAMPLE 9 Knockdown of LAT Levels Using ShRNAs

To further analyze the role of LAT levels in signaling downstream of theTCR, siRNAs and shRNAs targeted to LAT were designed and transfected inJurkat E6.1 cells. As shown in FIG. 9A, cells transfected with anon-targeting siRNA showed a robust influx of cytosolic Ca⁺⁺ upon CD3stimulation. In contrast, transfection with either a pool of 4 siRNAstargeting LAT (siPool) or a single LAT targeting siRNA (si2 and si4)effectively abrogated cytosolic Ca⁺⁺ flux. Of note, siRNA targeting ofLAT caused a 80-90% decrease in LAT levels as evaluated by western blot.

To enable us to evaluate the effect of decreasing LAT levels in acontrolled manner, we generated plasmids in which shRNA to LAT and GFPwere expressed simultaneously. This expression system allowed for cellsorting with gating based on GFP expression in the cell. Higher GFPlevels correlates with higher shRNA expression and thus, inverselycorrelates with LAT protein levels. Of note, LAT protein level in cellsincluded in gate C (GC) in FIG. 9B and FIG. 9C corresponds to backgroundlevels of LAT expression in LAT deficient Jurkat JCam2.5 cells. JurkatE6.1 cells were transfected with shRNA GFP plasmids and cytosolic Ca⁺⁺influx was measured in cells gated into three groups based on increasingGFP expression: gate A (GA), gate B (GB) and gate C (GC). Of interest,higher levels of GFP in the cell corresponded with decreased Ca⁺⁺ influxin response to CD3 stimulation (FIG. 8B and FIG. 8C). These datademonstrate that LAT expression has a dose-dependent effect on proximalsignaling downstream of the TCR. This result is consistent withincreased signaling observed in cells expressing LAT 2KR mutant that hasa degradation defect and accumulates to higher levels in cells.

Jurkat E6.1 cells in which LAT has been knocked down by the shRNA GFPexpression system described are reconstituted with wild-type or 2KR LATtagged with a fluorescent protein. This knockdown re-expression systemenables us to evaluate the effects of increasing levels of LAT knockdownby gating on GFP levels and at the same time evaluate the effect ofreconstitution of different levels of wild-type and mutant LAT in theknockdown cells. This experiment gives us an entire matrix ofinformation from which we can evaluate the effects of reconstitution ofparticular doses of wild-type and 2KR LAT at a given dose of LATknockdown. Thus, by gating on equal levels of reconstituted wild-type ormutant protein at a given level of knockdown, we are able to investigatewhether the 2KR LAT is a more potent signaling molecule, or whether theincreased signaling in the 2KR cells is due to increased levels of LATexpression, or a combination of the two. Various readouts are used forevaluating TCR signaling such as cytosolic Ca⁺⁺ influx, CD69 levels,CD25 levels, NFAT and NF-KB luciferase assays, intracellular IL-2 levelsand levels of phosphorylated signaling proteins.

EXAMPLE 10 Evaluation of TCR Signaling in Primary Human T Cells with LATKnocked Down and Reconstituted with Wild-Type or 2KR Mutant LAT

Primary human PBLs are transfected with LAT knockdown constructs andwild-type or 2KR LAT as described above for expression in Jurkat cells.Results from Jurkat E6.1 cells are confirmed in primary T cells. It isexpected that the expression of wild-type or ubiquitin defective LAT, orinhibition of expression of LAT, has the same effect on T-cell signalingin primary cells as in Jurkat cells.

EXAMPLE 11 Evaluation of TCR Signaling in Peripheral T Cells in 2KR LATTransgenic Mice

To investigate the role of LAT ubiquitylation in vivo, we have generatedtransgenic mice expressing wild-type and ubiquitin-defective LAT.Methods to generate transgenic mice are well known in the art, see,e.g., Manipulating the Mouse Embryo: A Laboratory Manual (Andras Nagy etal., Cold Spring Harbor Laboratory Press; 3 edition, 2002). Thetransgenic mice and cells from the transgenic mice are used toinvestigate signaling in various T cell populations and compared to miceexpressing wild-type LAT. Wild-type and ubiquitin defective LAT wasexpressed at various levels under the control of the distal Lckpromoter, which is expressed late in thymic development, to getexpression in mature T cells, thus enabling us to avoid thymic selectionwhich might eliminate more potent T cells. Expression in mature T cellsbypasses this developmental process.

Analysis of 2KR LAT transgenic mice demonstrate that mature 2KR LATcontaining T cells have enhanced TCR-dependent signaling compared withtheir wild-type counterparts.

EXAMPLE 12 Evaluation of T Cell Development in 2KR LAT Transgenic Mice

Transgenic mice expressing a ubiquitin-defective LAT protein, e.g., 2KRLAT are generated using routine methods. To investigate the role of LATubiquitylation in T cell development, wild-type and 2KR LAT areexpressed under the control of the human CD2 promoter that expressesearly in development. T cell development is evaluated by assessment ofvarious cell surface markers such as CD4 and CD8. If the numbers asassessed by these markers are different from those seen in wild typemice at various stages of development, we conclude that T celldevelopment is affected by the LAT 2KR mutation. However, if the numbersof cells at various stages of development are the same, it is stillpossible that development is affected, but the effects on positive andnegative selection cancel each other out. Therefore, positive andnegative selection is also evaluated by crossing wild-type and 2KRtransgenic mice onto the histocompatibility Y antigen (HY)-TCRtransgenic background in which the female mice exhibit positiveselection of T cells bearing the Tg TCR, while the male mice shownegative selection of such T cells.

EXAMPLE 13 Evaluation of Anti-Viral and Anti-Tumor Function of 2KR LAT TCells in Mouse Models

Wild-type and 2KR LAT transgenic mice are exposed to viral challenge,carcinogenic insult, and/or implanted with a xenograft tumor. Theability of T cells in these mice to effectively respond to thesechallenges is evaluated. Normal mice are used for controls in theseexperiments. In addition mice bearing only transgenic T cell receptorsare crossed to the LAT transgenic animal and these mice bearingtransgenic TCRs as well as wild-type or 2KR LAT are used for both cancerand viral infection models. These transgenic antigen receptors arespecific for known cancer or viruses. It is expected that the presenceof the 2KR LAT mutation will enhance clearance of tumor and/or virusesand thus results in a superior response both in the setting of thenormal immune response in the case of normal animals and the response ofspecific TCRs in the case of the transgenic mice.

Various mouse models of viral infection are used. For LCMV acuteinfection experiments, wild-type and 2KR transgenic mice are infectedwith various doses of virus (2×105 pfu of LCMV Armstrong strain i.p.).Viral titers are determined by standard plaque assay at various timesafter initial infection. In addition, response to viral infections aremeasured by evaluating numbers of virus-specific CD8+ T cells in spleenover time, levels of IFN-□ produced and cytolytic activity of CD8+ Tcells.

Various tumor models are used. For lung cancer model, TC1 cells areinjected into mice sub-cutaneously. For tumor clearance experiments,tumor diameters are measured 1-4 weeks after implantation, tumor volumesare calculated, and mouse viability is tracked. Numbers oftumor-specific CD8+ cells are measured using specific reagents(tetramers), levels of IFN-□ produced and cytolytic activity of these Tcells are measured. In addition, melanoma, prostrate, breast and othertumor models are tested.

It is expected that 2KR transgenic mice will have better viral and tumorclearance than wild-type LAT expressing mice.

In addition, mice bearing only transgenic T cell receptors are crossedto LAT transgenic animals and mice bearing transgenic TCRs as well aswild-type or 2KR LAT are used for both cancer and viral infectionmodels. These transgenic antigen receptors are specific for known canceror viruses and have been reported to have moderate effects on tumor orviral clearance. It is expected that the presence of the 2KR LATmutation will enhance clearance of tumor and/or viruses as assessedabove. In some cases, RAG KO mice are exposed to viral or tumorchallenge. This allows comparison of antitumor or antiviral effects ofpure populations of CD4 and CD8 cells against the same tumor antigen inthe absence of other T cells. One day after challenge, mice receivecells from freshly isolated spleens or lymph nodes of the TCR transgenicmice specific for the tumor or viral antigen and containing variousdoses of wild-type or 2KR LAT. Viral and tumor clearance are evaluatedas described above.

EXAMPLE 14 Evaluation of Ability of 2KR LAT to More Effectively CauseCancer Regression in Subjects with Metastatic Melanoma

Highly selected tumor-reactive T cells directed against overexpressedself-derived differentiation antigens are used for adoptive transferapproaches to combat metastatic melanoma are transfected/transduced with2KR LAT. Transferred cells are monitored in vivo for their abihty toproliferate, traffic to tumor sites and display functional activity.Regression rates of the subjects' metastatic melanoma are evaluated.

EXAMPLE 15 Evaluation of Signaling, Anti-Viral and Anti-Tumor Functionof 2KR LAT in Genetically Engineered T Cells

Adoptive immunotherapy is a promising approach for the treatment ofmelanoma and some other cancers. This approach overcomes thedifficulties associated with the isolation and expansion oftumor-reactive T cells in cancer patients. Instead, peripheral blood Tcells are retargeted to any chosen tumor antigen by the genetic transferof an antigen-specific receptor. The transduced receptors may bechimeric antigen receptors (CARs), designed to ligate tumor-associatedantigens using antibody fragments fused to a component of the TCRcomplex, or human leukocyte antigen-restricted, heterodimeric T-cellantigen receptor (TCRs).

Wild-type and 2KR constructs have been cloned into RNA transcription andlentiviral expression vectors. Chimeric Antigen Receptor (CAR)expressing T cells are transduced with wild-type or 2KR LAT and varioussignaling outputs such as CD69 upregulation and IL-2 production areevaluated upon stimulation via CD3 or surrogate antigen. Wild-type and2KR LAT are also tested in the context of CAR or MHCI restricted TCRs invivo in mouse tumor models to evaluate anti-tumor efficacy. The presenceof the 2KR LAT mutation enhances the clearance of tumors, reducing tumorburden and extending life.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents areintended to be encompassed by the following claims.

REFERENCES

All references, patents, patent publications, and sequence referencenumbers cited herein are incorporated herein by reference.

-   Aguilar, R. C., and B. Wendland. 2003. Ubiquitin: not just for    proteasomes anymore. Curr. Opin. Cell Biol. 15:184-190.-   Alarcon, B., and M. Fresno. 1998. Transferrin receptor (CD71), p.    2389-2392. In P. J. Delves and I. M. Roitt (ed.), Encyclopedia of    immunology, 2^(nd) ed. Academic Press, London, United Kingdom.-   Andoniou, C. E., N. L. Lill, C. B. Thien, M. L. Lupher, Jr., S.    Ota, D. D. Bowtell, R. M. Scaife, W. Y. Langdon, and H. Band. 2000.    The Cbl protooncogene product negatively regulates the Src-family    tyrosine kinase Fyn by enhancing its degradation. Mol. Cell. Biol.    20:851-867.-   Andoniou, C. E., C. B. Thien, and W. Y. Langdon. 1994. Tumour    induction by activated abl involves tyrosine phosphorylation of the    product of the cbl oncogene. EMBO J. 13:4515-4523.-   Barda-Saad, M., A. Braiman, R. Titerence, S. C. Bunnell, V. A. Barr,    and L. E. Samelson. 2005. Dynamic molecular interactions linking the    T cell antigen receptor to the actin cytoskeleton. Nat. Immunol.    6:80-89.-   Barr, V. A., L. Balagopalan, M. Barda-Saad, R. Polishchuk, H.    Boukari, S. C. Bunnell, K. M. Bernot, Y. Toda, R. Nossal, and L. E.    Samelson. 2006. T-cell antigen receptor-induced signaling complexes:    internalization via a cholesterol-dependent endocytic pathway.    Traffic 7:1143-1162.-   Bonello, G., N. Blanchard, M. C. Montoya, E. Aguado, C.    Langlet, H. T. He, S. Nunez-Cruz, M. Malissen, F. Sanchez-Madrid, D.    Olive, C. Hivroz, and Y. Collette. 2004. Dynamic recruitment of the    adaptor protein LAT: LAT exists in two distinct intracellular pools    and controls its own recruitment. J. Cell Sci. 117:1009-1016.-   Braiman, A., M. Barda-Saad, C. L. Sommers, and L. E. Samelson. 2006.    Recruitment and activation of PLCγ1 in T cells: a new insight into    old domains. EMBO J. 25:774-784.-   Brignatz, C., A. Restouin, G. Bonello, D. Olive, and Y.    Collette. 2005. Evidences for ubiquitination and intracellular    trafficking of LAT, the linker of activated T cells. Biochim.    Biophys. Acta 1746:108-115.-   Bunnell, S. C., D. I. Hong, J. R. Kardon, T. Yamazaki, C. J.    McGlade, V. A. Barr, and L. E. Samelson. 2002. T cell receptor    ligation induces the formation of dynamically regulated signaling    assemblies. J. Cell Biol. 158:1263-1275.-   Campi, G., R. Varma, and M. L. Dustin. 2005. Actin and agonist MHC    peptide complex-dependent T cell receptor microclusters as scaffolds    for signaling. J. Exp. Med. 202:1031-1036.-   Douglass, A. D., and R. D. Vale. 2005. Single-molecule microscopy    reveals plasma membrane microdomains created by protein-protein    networks that exclude or trap signaling molecules in T cells. Cell    121:937-950.-   Duan, L., A. L. Reddi, A. Ghosh, M. Dimri, and H. Band. 2004. The    Cbl family and other ubiquitin ligases: destructive forces in    control of antigen receptor signaling. Immunity 21:7-17.-   Dunn, R., and L. Hicke. 2001. Multiple roles for Rsp5p-dependent    ubiquitination at the internalization step of endocytosis. J. Biol.    Chem. 276:25974-25981.-   Ehrlich, L. I., P. J. Ebert, M. F. Krummel, A. Weiss, and M. M.    Davis. 2002. Dynamics of p561ck translocation to the T cell    immunological synapse following agonist and antagonist stimulation.    Immunity 17:809-822.-   Fang, D., and Y. C. Liu. 2001. Proteolysis-independent regulation of    PI3K by Cbl-b-mediated ubiquitination in T cells. Nat. Immunol.    2:870-875.-   Geisler, C. 2004. TCR trafficking in resting and stimulated T cells.    Crit. Rev. Immunol. 24:67-86.-   Govers, R., T. ten Broeke, P. van Kerkhof, A. L. Schwartz, and G. J.    Strous. 1999. Identification of a novel ubiquitin conjugation motif,    required for ligand-induced internalization of the growth hormone    receptor. EMBO J. 18:28-36.-   Haglund, K., P. P. Di Fiore, and I. Dikic. 2003. Distinct    monoubiquitin signals in receptor endocytosis. Trends Biochem. Sci.    28:598-603.-   Hartgroves, L. C., J. Lin, H. Langen, T. Zech, A. Weiss, and T.    Harder. 2003. Synergistic assembly of linker for activation of T    cells signaling protein complexes in T cell plasma membrane    domains. J. Biol. Chem. 278:20389-20394.-   Heissmeyer, V., F. Macian, S. H. Im, R. Varma, S. Feske, K.    Venuprasad, H. Gu, Y. C. Liu, M. L. Dustin, and A. Rao. 2004.    Calcineurin imposes T cell unresponsiveness through targeted    proteolysis of signaling proteins. Nat. Immunol. 5:255-265.-   Hicke, L., and R. Dunn. 2003. Regulation of membrane protein    transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev.    Cell Dev. Biol. 19:141-172.-   Houtman, J. C., R. A. Houghtling, M. Barda-Saad, Y. Toda, and L. E.    Samelson. 2005. Early phosphorylation kinetics of proteins involved    in proximal TCR-mediated signaling pathways. J. Immunol.    175:2449-2458.-   Houtman, J. C., H. Yamaguchi, M. Barda-Saad, A. Braiman, B.    Bowden, E. Appella, P. Schuck, and L. E. Samelson. 2006.    Oligomerization of signaling complexes by the multipoint binding of    GRB2 to both LAT and SOS1. Nat. Struct. Mol. Biol. 13:798-805.-   Jang, I. K., and H. Gu. 2003. Negative regulation of TCR signaling    and T-cell activation by selective protein degradation. Curr. Opin.    Immunol. 15:315-320.-   Jeon, M. S., A. Atfield, K. Venuprasad, C. Krawczyk, R. Sarao, C.    Elly, C. Yang, S. Arya, K. Bachmaier, L. Su, D. Bouchard, R.    Jones, M. Gronski, P. Ohashi, T. Wada, D. Bloom, C. G.    Fathman, Y. C. Liu, and J. M. Penninger. 2004. Essential role of the    E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity    21:167-177.-   Keane, M. M., S. A. Ettenberg, M. M. Nau, P. Banerjee, M. Cuello, J.    Penninger, and S. Lipkowitz. 1999. cbl -3: a new mammalian cbl    family protein. Oncogene 18:3365-3375.-   Lee, K. H., A. R. Dinner, C. Tu, G. Campi, S. Raychaudhuri, R.    Varma, T. N. Sims, W. R. Burack, H. Wu, J. Wang, O., Kanagawa, M.    Markiewicz, P. M. Allen, M. L. Dustin, A. K. Chakraborty, and A. S.    Shaw. 2003. The immunological synapse balances T cell receptor    signaling and degradation. Science 302:1218-1222.-   Lupher, M. L., Jr., Z. Song yang, S. E. Samelson, L. C. Cantle,    and H. Band. 1997. The Cbl phosphotyrosine-binding domain selects a    D(N/D)XP motif and binds to the Try292 negative regulatory    phosphorylation site of ZAP-70. J. Biol. Chem. 272:33140-33144.-   MIRV-Shimmer, Y., L. Duan, N. L. Rao, A. L. Reddi, H. Shimmer, R.    Rotatable, B. J. Druker, A. Tsygankov, V. Band, and H. Band. 2003.    Cbl-mediated ubiquitylation and negative regulation of Vay. J. Biol.    Chem. 278:38495-38504.-   Montages, R., J. Both, A. Robert, and L. Orca. 1982. Non-coated    membrane imaginations are involved in binding and internalization of    cholera and tetanus toxins. Nature 296:651-653.-   Naramura, M., H. K. Hole, R.-J. Hu, and H. Gu. 1998. Altered thymic    positive selection and intracellular signals in Cbl-deficient mice.    Proc. Natl. Aced. Sci. USA 95:15547-15552.-   Rao, N., I. Dodge, and H. Band. 2002. The Cbl family of ubiquitin    ligases: critical negative regulators of tyrosine kinase signaling    in the immune system. J. Leukoc. Biol. 71:753-763.-   Rao, N., S. Miyake, A. L. Reddi, P. Douillard, A. K. Ghosh, I. L.    Dodge, P. Zhou, N. D. Fernandes, and H. Band. 2002. Negative    regulation of Lck by Cbl ubiquitin ligase. Proc. Natl. Aced. Sci.    USA 99:3794-3799.-   Roose, J. P., M. Diehn, M. G. Tomlinson, J. Lin, A. A. Alizadeh, D.    Botstein, P. O. Brown, and A. Weiss. 2003. T cell    receptor-independent basal signalingvia Erk and Abl kinases    suppresses RAG gene expression. PLoS Biol. 1:E53.-   Samelson, L. E. 2002. Signal transduction mediated by the T cell    antigen receptor: the role of adapter proteins. Annu. Rev. Immunol.    20:371-394.-   Sommers, C. L., J. Lee, K. L. Steiner, J. M. Gurson, C. L.    Depersis, D. El-Khoury, C. L. Fuller, E. W. Shores, P. E. Love,    and L. E. Samelson. 2005. Mutation of the phospholipase C-γ1-binding    site of LAT affects both positive and negative thymocyte    selection. J. Exp. Med. 201:1125-1134.-   Tanimura, N., M. Nagafuku, Y. Minaki, Y. Umeda, F. Hayashi, J.    Sakakura, A. Kato, D. R. Liddicoat, M. Ogata, T. Hamaoka, and A.    Kosugi. 2003. Dynamic changes in the mobility of LAT in aggregated    lipid rafts upon T cell activation. J. Cell Biol. 160:125-135.-   Thien, C. B., F. D. Blystad, Y. Zhan, A. M. Lew, V. Voigt, C. E.    Andoniou, and W. Y. Langdon. 2005. Loss of c-Cbl RING finger    function results in high intensity TCR signaling and thymic    deletion. EMBO J. 24:3807-3819.-   Thien, C. B., D. D. Bowtell, and W. Y. Langdon. 1999. Perturbed    regulation of ZAP-70 and sustained tyrosine phosphorylation of LAT    and SLP-76 in c-Cbl-deficient thymocytes. J. Immunol. 162:7133-7139.-   Thien, C. B., and W. Y. Langdon. 2005. c-Cbl and Cbl-b ubiquitin    ligases: substrate diversity and the negative regulation of    signalling responses. Biochem. J. 391:153-166.-   Thien, C. B., and W. Y. Langdon. 2005. Negative regulation of PTK    signaling by Cbl proteins. Growth Factors 23:161-167.-   van Leeuwen, J. E., P. K. Paik, and L. E. Samelson. 1999. Activation    of nuclear factor of activated T cells-(NFAT) and activating protein    1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine    binding domain but not Crk(L) or p85 phosphatidylinositol 3-kinase    association. J. Biol. Chem. 274:5153-5162.-   van Leeuwen, J. E., P. K. Paik, and L. E. Samelson. 1999. The    oncogenic 70Z Cbl mutation blocks the phosphotyrosine binding    domain-dependent negative regulation of ZAP-70 by c-Cbl in Jurkat T    cells. Mol. Cell. Biol. 19: 6652-6664.-   Varma, R., G. Campi, T. Yokosuka, T. Saito, and M. L. Dustin. 2006.    T cell receptor-proximal signals are sustained in peripheral    microclusters and terminated in the central supramolecular    activation cluster. Immunity 25:117-127.-   Veillette, A., S. Latour, and D. Davidson. 2002. Negative regulation    of immunoreceptor signaling. Annu. Rev. Immunol. 20:669-707.-   Wilson, B. S., J. R. Pfeiffer, Z. Surviladze, E. A. Gaudet,    and J. M. Oliver. 2001. High resolution mapping of mast cell    membranes reveals primary and secondary domains of Fc(epsilon)RI and    LAT. J. Cell Biol. 154:645-658.-   Wu, J. N., and G. A. Koretzky. 2004. The SLP-76 family of adapter    proteins. Semin. Immunol. 16:379-393.-   Yokosuka, T., K. Sakata-Sogawa, W. Kobayashi, M. Hiroshima, A.    Hashimoto-Tane, M. Tokunaga, M. L. Dustin, and T. Saito. 2005. Newly    generated T cell receptor microclusters initiate and sustain T cell    activation by recruitment of Zap70 and SLP-76. Nat. Immunol.    6:1253-1262.-   Yokouchi, M., T. Kondo, A. Houghton, M. Bartkiewicz, W. C. Home, H.    Zhang, A. Yoshimura, and R. Baron. 1999. Ligand-induced    ubiquitination of the epidermal growth factor receptor involves the    interaction of the c-Cbl RING finger and UbcH7. J. Biol. Chem.    274:31707-31712.-   Zhang, W., J. Sloan-Lancaster, J. Kitchen, R. P. Trible, and L. E.    Samelson. 1998. LAT: the ZAP-70 tyrosine kinase substrate that links    T cell receptor to cellular activation. Cell 92:83-92.-   Zhang, W., R. P. Trible, and L. E. Samelson. 1998. LAT    palmitoylation: its essential role in membrane microdomain targeting    and tyrosine phosphorylation during T cell activation. Immunity    9:239-246.-   Zhang, W., R. P. Trible, M. Zhu, S. K. Liu, C. J. McGlade, and L. E.    Samelson. 2000. Association of Grb2, Gads, and phospholipase C-γ1    with phosphorylated LAT tyrosine residues. Effect of LAT tyrosine    mutations on T cell antigen receptor-mediated signaling. J. Biol.    Chem. 275:23355-23361.-   Hershko A, and Ciechanover A.1998. The ubiquitin system. Annu Rev    Biochem. 1998; 67:425-79.-   Balagopalan L, Barr V A, Sommers C L, Barda-Saad M, Goyal A,    Isakowitz M S, and Samelson L E. 2007. c-Cbl-mediated regulation of    LAT-nucleated signaling complexes. Mol Cell Biol. 2007 December;    27(24):8622-36.-   Hogquist Ka, Baldwin Ta, Jameson Sc. 2005. Central Tolerance:    Learning Self-Control In The Thymus.Nat Rev Immunol. October;    5(10):772-82.

1-50. (canceled)
 51. A therapeutic composition comprising a T-cellhaving increased signaling through the T-cell receptor, said T-cellcomprising a ubiquitin-deficient LAT (linker for activation of T cells)or an effective fragment thereof, wherein the ubiquitin-deficient LAT oreffective fragment thereof comprises the polypeptide of SEQ ID NO: 1 oran effective fragment thereof, having at least one amino acidsubstitution at a site selected from the group consisting of amino acid52 and amino acid
 204. 52. The therapeutic composition of claim 51,wherein the amino acid substitution at amino acids 52 and 204 are aminoacids not capable of being ubiquitylated.
 53. The therapeuticcomposition of claim 51, wherein the amino acid substitution at aminoacids 52 and 204 are each arginine (R).
 54. The therapeutic compositionof claim 51, wherein the T-cell further comprises an expressionconstruct encoding the ubiquitin-deficient LAT or effective fragmentthereof.
 55. The therapeutic composition of claim 54, wherein theexpression construct comprises a nucleic acid molecule encoding (a) thepolypeptide of SEQ ID NO: 1 or an effective fragment thereof, having atleast one amino acid substitution at a site selected from the groupconsisting of amino acid 52 and amino acid
 204. 56. The therapeuticcomposition of claim 55, wherein the expression construct includes aT-cell specific promoter for expression of the ubiquitin-deficient LAT.57. The therapeutic composition of claim 56, wherein the promoter isselected from the group consisting of human CD2, distal Lck, andproximal Lck.
 58. The therapeutic composition of claim 51, wherein theT-cell is an autologous T-cell with anti-tumor activity.
 59. Thetherapeutic composition of claim 51, wherein the T-cell is an allogenicT-cell with anti-tumor activity.
 60. A therapeutic compositioncomprising a tumor-reactive T-cell for Adoptive Cell Therapy (ACT) forthe treatment of cancer, wherein said tumor-reactive T-cell expresses aubiquitin-deficient LAT (linker for activation of T cells) or aneffective fragment thereof, wherein the ubiquitin-deficient LATcomprises a mutated ubiquitylation site.
 61. The therapeutic compositionof claim 60, wherein the ubiquitin-deficient LAT comprises (a) thepolypeptide of SEQ ID NO: 1 or an effective fragment thereof, having atleast one amino acid substitution at a site selected from the groupconsisting of amino acid 52 and amino acid 204, or (b) the polypeptideof SEQ ID NO: 2 or an effective fragment thereof, having at least oneamino acid substitution at a site selected from the group consisting ofamino acid 53 and amino acid
 121. 62. The therapeutic composition ofclaim 61, wherein the amino acid substitution at amino acids 52, 53,121, and 204 are amino acids not capable of being ubiquitylated.
 63. Thetherapeutic composition of claim 61, wherein the amino acid substitutionat amino acids 52, 53, 121, and 204 are each arginine (R).
 64. Thetherapeutic composition of claim 60, wherein the T-cell furthercomprises an expression construct encoding the ubiquitin-deficient LAT.65. The therapeutic composition of claim 64, wherein the expressionconstruct comprises a nucleic acid molecule encoding (a) the polypeptideof SEQ ID NO: 1 or an effective fragment thereof, having at least oneamino acid substitution at a site selected from the group consisting ofamino acid 52 and amino acid 204, or (b) the polypeptide of SEQ ID NO: 2or an effective fragment thereof, having at least one amino acidsubstitution at a site selected from the group consisting of amino acid53 and amino acid
 121. 66. The therapeutic composition of claim 64,wherein the expression construct includes a T-cell specific promoter forexpression of the ubiquitin-deficient LAT.
 67. The therapeuticcomposition of claim 66, wherein the promoter is selected from the groupconsisting of human CD2, distal Lck, and proximal Lck.
 68. Thetherapeutic composition of claim 60, wherein the T-cell is an autologousT-cell with anti-tumor activity.
 69. The therapeutic composition ofclaim 60, wherein the T-cell is an allogenic T-cell with anti-tumoractivity.